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ABSTRACT 
 
Despite the advent of highly active antiretroviral therapy (HAART), neurological 
disorders develop in most people infected with human immunodeficiency virus type 1 
(HIV-1). The poor CNS delivery of anti-retrovirals allows continued virus production and 
renders neurons susceptible to the toxic effects of released viral proteins. The neurotoxic 
potential of HIV-1 viral protein Tat has been shown to include excitotoxicity, oxidative 
stress, and mitochondrial dysfunction leading to subsequent cell death. Thus, Tat is 
thought to have a key role in the pathogenesis of HIV-associated neurodegeneration. 
Estrogens are universally considered to be neuroprotective, as such; estrogens have 
positive implications in the treatment of neurodegenerative disease, as well as acute 
neuronal death. Estrogen neuroprotective mechanisms may include a direct neuronal anti-
apoptotic effect as estrogen modulates actions of key regulators of the 
mitochondrial/intrinsic apoptotic cascade. However, estrogen therapy is associated with 
increased risk of breast and uterine cancers. Estrogen receptors (ERs) are present in the 
brain and are thought to mediate estrogen protective actions. Compounds that selectively 
target estrogens protective effects without eliciting its negative side effects may serve as 
viable therapeutic options.  
In the present study, we tested the ability of estrogen and phytoestrogens 
 
 
vii 
(genistein and daidzein) to protect against apoptotic signaling in cortical cell cultures 
exposed to Tat 1-86 (50 nM), and additionally, whether the beneficial actions of estrogen 
and phytoestrogens involved an estrogen receptor sensitive mechanism. We demonstrated 
that estrogen pretreatment significantly delayed Tat-induced cell death in primary cortical 
cultures.  Pretreatment with 17β-estradiol or phytoestrogens attenuated the increased 
expression of anti-apoptotic protein Bcl-2, pro-apoptotic protein Bax and activation of 
caspases linked to mitochondrial apoptotic pathway following Tat exposure. In addition, 
select components of apoptotic pathway signaling appear more sensitive to estrogen 
receptor (ER) activation, as the addition of ER antagonist ICI182,780 reversed 
downregulation of Bax and caspase 3, while effects on Tat-induced Bcl-2 and caspase 9 
expression were maintained.  Moreover, the addition of preferential ERα and ERβ 
antagonists (MPP dihydrochloride and PHTPP) indicated that 17β-estradiol and 
phytoestrogen effects on caspase 3 may be mediated by both receptor subtypes, while 
ERβ was more involved in effects on Bax.  Our data suggest that 17β-estradiol and 
phytoestrogen are able to intervene against HIV Tat-induced cortical neuronal 
dysfunction via intersecting mitochondrial apoptotic pathway signaling in an ER-
sensitive manner.  
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CHAPTER 1 
1. Introduction 
1.1. HIV-1 infection and consequences for the central nervous system  
Over 33 million people worldwide are infected by HIV (UNAIDS/WHO), and 
while HIV is most well known for its devastating effects on the immune system and the 
resulting AIDS, it can also cause several neurological disorders, collectively known as 
HIV-associated neurocognitive disorders (HAND) (Dewhurst et al., 1996; Gray et al., 
2001).  HAND syndromes are characterized by cognitive, motor and behavioral 
abnormalities (Kaul et al., 2005) and are classified according to patient performance in 
areas of neurological and behavioral functioning and neuropsychological testing (Sacktor 
et al., 2001; Sactor, 2002; McArthur, 2004).  Prior to the advent of highly active 
antiretroviral therapy (HAART), 20-30% of individuals with advanced HIV infection 
displayed symptoms of the severe HAND, HIV-associated dementia (HAD) (Kaul et al., 
2005; Gonzalez-Scarano and Martin-Garcia, 2005). With the widespread use of HAART, 
the incidence of HAD has dramatically decreased; however, as many of 40% of HIV-
positive patients continue to suffer from HAND (Dewhurst et al., 1996; Gray et al., 2001; 
Nath et al., 2008; Dewhurst et al., 1996; Gray et al., 2000; King et al., 2006; Li et al., 
2005).  Moreover, as the incidence of HAD has decreased, its prevalence is actually 
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increasing, due in part to the longer life expectancy of HIV-infected persons and to 
patient resistance to HAART drugs (Gonzalez-Scarano and Martin-Garcia, 2005; Gray et 
al., 2003; MacArthur et al., 2003; Sacktor et al., 2002; Maschke et al., 2000).  The 
continued prevalence of milder forms of HAD suggests a shift in the distribution of 
HAND subtypes in the post-HAART era.  In patients presenting even the milder forms of 
HAND, quality of life is greatly affected, with these individuals suffering from 
disruptions in ability to perform activities of daily living, perhaps most importantly, that 
of adherence to the HAART regiment (MacArthur, 2004).  Manifestation of mild 
cognitive/motor disorder (MCMD) appears to indicate a worse prognosis for AIDS and 
has been highly correlated with the subsequent development of HAD and the detection of 
HIVE at autopsy (Sactor et al., 1996; Cherner et al., 2002).  This continued prevalence of 
neurological dysfunction, suggests HAART fails to provide complete protection from the 
development of HAD (Antorini et al., 2007; Ellis et al., 1997; Liner et al., 2008; Boisse et 
al., 2008).   This failure to prevent the deterioration or enable restoration of cognitive 
function has been linked to limited penetration of many antiretroviral drugs in the CNS 
(Enting et al., 1998). It is also of note that HAART, in the long term, poses a potential 
toxicological problem that may affect neurocognitve performance. Although HAART has 
impacted on the incidence of HAD, it still remains a serious concern during AIDS.  A 
recent study reported that 90% of HIV-1 infected patients that died between 1996 and 
2001 were newly diagnosed with HAD within 12 months of death (Welch and Morse, 
2002). It is suggested that HAD is the most common form of dementia worldwide in 
people aged 40 years or less, and is a significant independent risk factor for death due to 
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AIDS (Ellis et al., 1997).  
1.2. Pathology of HIV in CNS 
HAD manifests as subcortical dementia characterized by psychomotor slowing, 
changes in mood and anxiety levels, deficits in memory, information processing, verbal 
fluency, decision making and attention ( Navia et al., 1986; Grant et al., 1987; Price et al., 
1988; Portegies et al., 1993).  With such a range of symptoms, numerous brain regions 
commonly damaged in HAD are basal ganglia, deep white matter, hippocampus, and 
cerebral cortex (Berger et al., 2000; Dewhurst et al., 1996; Gray et al., 2001; Gray et al., 
2003; Maschke et al., 2004; Sporer et al., 2005).  Pathological features of HAD include 
multinucleated giant cells, activated microglia, dendritic simplification, and cell death 
(Kaul et al., 2005(Archibald et al., 2004).  Clinical signs of HAD are more closely 
associated with increased numbers of microglia, evidence of excitotoxins, and selective 
neuronal damage and loss, rather than correlating with viral load in the CNS.   
Cerebral atrophy and white matter abnormalities are common neuroimaging 
findings among HIV-infected individuals, and are evident in both cortical and subcortical 
regions of the brain (Paul et al., 2002). Several reports have shown large neuronal loss in 
cortical regions in AIDS (Everall et al., 1991; Everall et al., 1993; Fischer et al., 1999; 
Moore et al., 2006). In some studies, the severity of atrophy was correlated with 
advanced stages of HIV-1 infection or with clinical signs of cognitive impairment.  
Volumetric MRI analysis has shown that cortical atrophy associated with HIV infection 
might be caused by neuron loss and demyelination (Arendt and Nolting, 2008; Arendt, 
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1995; Bornstein et al., 1992; Boska et al., 2004; Chang et al., 2002; Chiang et al., 1998; 
Costello et al., 2007; Dal Pan et al., 1992; Di, V et al., 1997; Elovaara et al., 1990; Ernst 
et al., 2002).  Synaptodendritic loss will reduce the overall volume of brain gray and 
white matter.  In HIV-infected individuals, the degree of neurocognitive impairment was 
strongly related to loss of immunostaining for synaptophysin and MAP2, pre and post 
synaptic proteins, respectively (Arendt and Nolting, 2008; Arendt, 1995; Bornstein et al., 
1992; Boska et al., 2004).  The degree of atrophy is correlated to the degree of cognitive 
motor dysfunction. Quantitative MRI shows a correlation between cerebral atrophy and 
neuropsychological performance (Ho and Jay, 2010; Dewey et al., 2010; Johnson and 
Nath, 2010; Ances et al., 2010; Gongvatana et al., 2009; Descamps et al., 2008).  
Eventually, the correlation persists between an increase in atrophy and worsening in 
certain cognitive functions (Hall et al., 1996; Everall et al., 1999). Neuronal loss in the 
frontal cortex and in other regions of the neocortex has been estimated between 18 and 
38% (Everall et al., 1991; Ketzler et al., 1990).  Select neuronal subpopulations, 
including larger pyramidal cells within the cortex, are at greater risk of cell death and 
similarly neuronal populations that secrete certain neurotransmitters are more likely to be 
diminished in the HIV-1 infected brain (Masliah et al., 1992).   
1.3. Oxidative stress and HIV dementia 
There is overwhelming evidence that oxidative stress mediates neuronal injury 
and contributes to the pathogenesis of HIV dementia. Oxidative stress in HIV-dementia 
patients has been demonstrated in the brain and CSF (Chauhan et al., 2003; Turchan et 
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al., 2003; Pocernich et al., 2005; Steiner et al., 2006). Oxidative stress can be defined by 
the modification and accumulation of biological molecules altered by various reactive 
oxygen species (ROS) (Pocernich et al., 2005).  ROS are highly reactive, toxic oxygen 
moieties, such as hydrogen peroxide, peroxynitrite and superoxide anion. ROS can lead 
to oxidation of proteins and DNA, peroxidation of lipids and ultimately cell death. 
Protein carbonyl groups are used as a marker of protein oxidation, and they are generated 
from direct oxidation of amino acids or from binding of the lipid peroxidation product 4-
hydroxynonenal (HNE) to proteins (Pocernich et al., 2005).   Staining of  lipid 
peroxidation product HNE was found to be prominent  in neurons, glial cells, 
perivascular cells in brain slices of patients with HIV encephalitis (Turchan et al., 2003). 
Protein oxidation was increased in the CSF of HIV-patients with mild and severe 
dementia compared to non-demented patients. Nitrated tyrosine residues, evidence of 
peroxytnitrite reaction with proteins, is increased in HIVD brains (boven , 1999). It was 
recently reported that levels of ceramide, sphingomyelin, and HNE are significantly 
increased in brain and CSF of HAD patient, and the HIV protein Tat can induce increases 
of all three in cultured neurons (Haughey et al., 2004; boven , 1999).  Further, oxidative 
stress may be correlated with HIV-induced neuropsychological impairment (Turchan et 
al., 2003).  This is partly due not only to the fact that HIV proteins and immune activation 
mediates the accumulation of ROS, but also to the fact that some antiretroviral therapy 
based on nucleoside reverse transcriptase inhibitors (NRTI) has been shown to increase 
oxidative stress (Hulgan et al., 2003) and may be toxic to mitochondria (Lewis et al., 
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2003). 
 To counteract the damaging free radicals, antioxidant systems have evolved that 
include enzymes glutathione peroxidase, superoxide dismutase and catalase. Protection 
against oxidative stress also comes from small, nonprotein antioxidants, such as 
glutathione, vitamin C, flavonoids, and vitamin E (Butterfield and Stadtman, 1997). 
Antioxidant levels in HIV-infected patients are altered, and may lead to increase 
oxidative stress (Pocernich et al., 2005; Steiner et al., 2006).  Glutathione, which protects 
neurons from ROS and binds lipid peroxidation products such as HNE, has decreased 
levels in HIV patients (Drake et al., 2002; Pocernich et al., 2000). Serum glutathione 
levels and glutathione peroxidase activity are significantly reduced in HIV patients 
compared to controls while an increase in lipid peroxidation products and DNA 
fragmentation were increased (Gil et al., 2003). Additionally, levels of glutathione 
synthase are decreased in the liver, blood, and CNS of HIV-infected persons and low 
concentration of glutathione synthase has been correlated with poor survival in HIV 
infected patients (Herzenberg et al., 1997;Castagna et al., 1995). These data indicate the 
detrimental effects of oxidative stress in HIV infection, increases production of reactive 
oxygen species along with suppression of endogenous antioxidant systems.  
1.4. Tat 
Given that the HIV-1 virus does not directly infect neurons, it has been 
determined that detrimental effects in the brain are mediated by released toxic viral 
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products (King et al., 2006; van de Bovenkamp et al., 2002).  Both direct and indirect 
neurotoxic mechanisms are believed to operate in HIV-related neurotoxicity.  In the 
direct pathway, infected microglia and macrophages release viral particles and proteins, 
some of which have been shown to be neurotoxic in vitro. The viral molecules which are 
particularly implicated include gp120 and Tat.   
HIV-1 Tat is a viral nonstructural protein of 86-101 amino acids in length and it is 
the product of two exons. Tat, a transactivating nuclear regulatory protein, is critical for 
viral replication and is secreted by HIV-1 infected cells (King et al., 2006; Noonan and 
Albini, 2000; Wallace, 2006).  Secreted Tat may be taken up by neighboring cells, and in 
this manner, Tat is able to elicit affects on both infected and uninfected cells. The HIV-1 
protein Tat released from macrophages produces trimming of neurites, mitochondrial 
dysfunction, and cell death in neurons (Chauhan et al., 2003; (Aksenov et al., 2003; 
Aksenov et al., 2001a; Kruman et al., 1998). HIV Tat has been detected in sera of HIV-
infected patients at the low nanomolar level, in the range of 2ng/mL to 40 ng/mL (Wiley 
et al., 1996; Xiao et al., 2001).   
1.4.1 Tat-induced neurotoxicity 
Neuronal injury is a primary basis/component of many neurodegenerative 
diseases, including HAD. Given that the HIV-1 virus does not directly infect neurons, it 
has been determined that detrimental effects in the brain are mediated by released toxic 
viral products (King et al., 2006; van de Bovenkamp et al., 2002).  Several HIV-1 
encoded proteins, including the transcription transactivator Tat, have been demonstrated 
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to directly induce neuronal cell death. HIV-1 viral protein Tat can be released by HIV-
infected cells to the extracellular space, cerebrospinal fluid (CSF) and sera and is taken 
up by neurons (Chang et al., 1997; Ensoli et al., 1993; Sabatier et al., 1991). Tat has been 
detected in the brains of people with HIVE by mRNA and Western blotting analyses 
(Wiley et al., 1996; Hudson et al, 2000).   The HIV Tat protein is thought to play a 
significant role in HIV related neuropathology.  Tat is taken up by CNS cells, and often 
results in toxic consequences in both the cytoplasm and nucleus, including altered gene 
transcription, cytokine secretion, NMDAR activation in neurons, and the initiation of 
apoptotic cascades (Aksenov 2009; 2006; 2003; Silvers et al., 2007; Rappaport et al., 
1999; Kumar et al., 1999). A combination of these cellular events are likely involved in 
neuronal apoptosis in response to HIV-1 infection and the secretion of Tat, however the 
exact mechanism is not well understood.  
 Tat induced neurotoxicity is thought to be mediated by various mechanisms 
including excitotoxic mechanisms involving calcium and oxidative stress.  Tat toxicity  
has been associated with glutamate receptor activation, since antagonists of NMDA and 
non-NMDA receptors partially protect neurons from the toxic effects of  Tat (Haughey et 
al., 2001; Magnuson et al., 1995; Nath et al., 1996).  The neurotoxic effects of Tat are in 
part mediated by direct interactions with a polyamine-sensitive site on the NMDA 
receptor (Prendergast et al., 2001; Self et al., 2004).  Studies have also suggested that Tat 
neurotoxicity is dependent on binding to low-density receptor (LPR) with subsequent 
activation of NMDAR (King et al., 2006).  Several studies have shown that NMDAR 
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function may be modulated by dopamine D1-like receptors and a recent study has 
implicated D1-mediated pathways in the mechanism of Tat-induced neurotoxicity 
(Silvers et al, 2007).  HIV-1 Tat may influence the activity of D1 receptors in 
postsynaptic neurons, thereby trigger NMDAR-regulated apoptotic cascades via 
D1/NMDAR interaction or, alternatively, NMDAR activation in D1-expressing neurons 
exposed to Tat may upregulate pro-apoptotic D1-mediated signaling (Silvers et al., 2007). 
Tat has been shown to activate phosphatidylinositol 3-kinase, increase levels of IP3, 
release calcium from endoplasmic reticulum internal stores, and increase activity of PKC 
isoforms, all precursors of oxidative stress (Aversa et al., 2004; Haughey et al., 1999; 
Borgatti et al., 1998; Haughey and Mattson, 2002).   
Moreover, Tat exposure has been shown to increase markers of oxidative stress. 
Studies in our lab have demonstrated that striatal injections of Tat caused an increase in 
protein carbonyl formation that preceded Tat-mediated astrogliosis (Aksenov et al., 2001) 
and increased striatal tissue loss in rats (Bansal et al., 2000).   Tat induced protein and 
lipid peroxidation has also been detected in synaptosomal membranes and neuronal cell 
cultures (Pocernich et al., 2004). Oxidative stress is an early step in Tat neurotoxicity as 
increases protein oxidation soon after Tat exposure, followed by pronounced neuronal 
degeneration and activation of macrophages/microglia (Aksenov et al., 2003).  Tat may 
also compromise the functioning of antioxidant systems.  Tat plays a major role in the 
glutathione system as demonstrated by a downregulation of glutathione synthetase, 
stopping glutathione synthesis, in the liver of tat-transgenic mice (Aksenov et al., 2001b; 
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King et al., 2006; Noonan and Albini, 2000; Pocernich et al., 2005b; Pocernich et al., 
2005a; Steiner et al., 2006; Wallace, 2006; Choi et al., 2000). HeLa cells expressing Tat 
were found to have decreased glutathione peroxidase activity and mRNA levels and low 
levels Mn superoxide dismutase (Bouvard et al., 2002; Richard et al., 2001). Protein 
oxidation was increased and antioxidant systems were decreased in these HeLa –Tat 
cells, reflecting ongoing oxidative stress.  
1.4.2. Effect of HIV-1 viral protein Tat on mitochondria 
 Mitochondria are considered the powerhouses of the cell. They are responsible for 
generating energy as ATP and are key regulators of cell survival and death. Thus, 
mitochondria may have a central role in numerous neurodegenerative diseases. Damage 
to mitochondria is caused primarily by reactive oxygen species (ROS) generated by 
mitochondria.  Mitochondria consume 85% of the oxygen utilized by the cell during 
production of ATP (Shigenaga et al., 1994). Normally, 4% of all oxygen consumed is 
converted in mitochondria to the superoxide radical (Shigenaga et al., 1994; Evans et al., 
2002; Carreras et al., 2004). Superoxide is transformed to hydrogen peroxide by the 
detoxification enzymes Mn superoxide dismutase (Wallace, 2005) and then to water by 
glutathione peroxidase (Green et al., 2004).   However, when these enzymes cannot 
convert ROS to water fast enough, oxidative damage occurs and accumulates in the 
mitochondria (James and Murphy, 2002; Sies, 1993; Pieczenik and Neustadt, 2007). As 
mentioned previously, these endogenous antioxidant enzymes are compromised in HIV-
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infected patients.   
  A general mitochondrial effect of HIV-1 has been obtained by treating HIV-1 
transgenic mice with AZT, an anti-retroviral drug. AZT is discovered to negatively affect 
mitochondrial DNA replication and provoke persistent mitochondrial myopathy in AIDS 
patients. In mice, transgenic HIV sensitizes to AZT-induced myocardial 
mitochondriopathy (Kohler et al., 2009; Pupure et al., 2008; Chan et al., 2007; Collins et 
al., 2004). In Tat-expressing mice, AZT-treatment caused a greatly enhanced suppression 
of Mn superoxide dismutase (Prakash et al., 1997; Shi et al., 1998). In addition, Tat was 
found to exacerbate signs of AZT-induced oxidative stress(Prakash et al., 1997). Thus, 
HIV-1 and particularly Tat, can affect mitochondrial metabolism in vivo.  
 Cells stably transfected with Tat are more susceptible than control cells to 
undergo apoptosis upon serum withdrawal. According to one study, Tat causes a decrease 
in Bcl-2 expression and an increase in Bax expression (Sastry et al., 1996). Another study 
reports that Tat translocates to mitochondria concomitantly with the loss of mitochondrial 
membrane potential (Macho et al., 1999). Addition of extracellular Tat causes apoptosis 
(Li et al., 1995; Aksenov et al., 2009; Adams et al., 2010). Tat downregulates the 
mitochondrial isoform of superoxide dismutase (SOD2), either at the post-transcriptional 
or transcriptional levels (Briehl and Baker, 1996; Flores et al., 1993; Gil et al., 2003; 
Marecki et al., 2004). This downregulation of SOD is thought to sensitize cells to the 
lethal effects of reactive oxygen species produced in mitochondria.  Exogenous Tat can 
also induce the expression of pro-apoptotic proteins (Adams et al., 2010). These proteins 
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include Bax and Par-4, which induces apoptosis via a mitochondrion-dependent 
mechanism (Kruman et al., 1998;1999). These results suggest multiple connections of 
between Tat-induced cell death and mitochondria.   
Moreover, numerous studies suggest that Tat-induced cell death is mediated 
through the intrinsic/mitochondrial apoptotic pathway.  Tat has been shown to induce 
Ca2+ influx from the extracellular environment through various neuronal calcium 
channels (Bonavia et al., 2001; Haughey et al., 2001; Perez et al., 2001; Nath et al., 
1996). The elevation in cytosolic Ca2+ is an early event in neuronal apoptotic cascade 
and appears to trigger mitochondrial calcium uptake and subsequent mitochondrial 
dysfunction.  Studies in cultured embryonic rat hippocampal neurons demonstrated that 
HIV-1 Tat induced neuronal cell death involved caspase activation, disruption of Ca2+ 
homeostasis, and generation of mitochondrial reactive oxygen species (Kruman et al., 
1998a). 
1.5. Estrogen in neurodegeneration 
 Estrogens are primarily synthesized in the ovaries and in the suprarenal glands. 
The most potent and dominating estrogen is 17β-estradiol, but lower levels of estrone and 
estriol are also present (Gruber et al., 2002b). Following synthesis in the ovaries and 
suprarenal glands, 60% of estrogens are bound to plasma proteins and transported to the 
target tissue, including brain (McEwen, 2002; Gruber et al., 2002b).  Estrogens are 
lipophilic and have a low molecular weight, which enables them to diffuse freely through 
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the blood-brain barrier (Samii et al., 1994).   
 In the developing brain, estrogens control the differentiation and plasticity of 
distinct neuronal populations (Beyer, 1999). Estrogens promote growth in the 
hypothalamus, hippocampus, midbrain and cortex (McEwen and Alves, 1999).  In the 
adult CNS, in addition to its regulation of HPA and sexual behavior (Herbison, 1998), 
estrogens also powerfully influence cognition-related neuronal activity, and the 
modulation of mood, mental state and learning, and memory (Brinton, 2001; McEwen et 
al., 1995; McEwen et al., 2001).  
Gender differences have been associated with decreased risk, delayed onset and 
progression, or enhanced recovery from numerous traumatic or chronic neurological and 
mental diseases. This involves many different types of diseases, classified as 
neurotransmitter system abnormalities, disorders caused by trauma (stroke) or by defects 
in the immune or cardiovascular systems, and neurodegenerative diseases (Rogers and 
Wagner, 2006; Farooque et al., 2006; Chen et al., 2005; Wooten et al., 2004; Bayir et al., 
2004). Although the reason for the gender difference in these diseases is still unknown, 
the concentration of estrogen may be involved, or the expression of their receptors.  
Collateral support for a neuroprotective role of endogenous E2 has also arisen 
from observations of greater brain damage in males than in female animals in ischemic 
stroke models (Dubal et al., 1998; Zhang et al., 1998; Rusa et al., 1999; Alkayed et al., 
2000).  Moreover, estrogen deficiency as seen during menopause has been correlated 
with increased incidence of stroke and cognitive defects, mood changes, and early onset 
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and severity of Alzheimer’s (Correia et al., 2010; Aenlle et al., 2009; Rocca et al., 2007; 
Solenski, 2007; Genazzani et al., 2007). 
1.5.1. Neuroprotective role of estrogen  
There is recent yet still controversial evidence that estrogen treatment reduces the 
risk and delays the onset of some neurodegenerative diseases. In Alzheimer’s disease 
(AD), the decline of estrogens is related to the risk of this disease in post-menopausal 
women (Tang et al., 1996). Early epidemiological evidence supported a role for estrogen 
replacement therapy (ERT) in reducing the incidence of AD in these women.  Moreover, 
several studies indicated that ERT improves performance in some memory/cognition tests 
in AD patients (Henderson et al., 1995; Yaffe et al., 1998; Costa et al., 1999).  
Both epidemiological and clinical reports indicate a positive role for estrogen use 
in Parkinson’s disease (PD) (Saunders-Pullman et al., 1999).  Reduction of estrogen 
supplementation in postmenopausal women causes a worsening of Parkinson-related 
symptoms, and the severity  of symptoms in women with early PD is diminished by the 
application of estrogens (Morale et al., 2006).  The neuroprotective acts of estrogen on 
the dopaminergic system may be indicated by epidemiological reports showing a sex 
difference in PD, as it is reported that PD has greater prevalence in males (Bourque et al., 
2009; Dluzen, 2000; Liu et al., 2005; Miller et al., 1998; Sawada et al., 2002; Sawada et 
al., 1998).  
Experimental investigations strongly support the idea that estrogens may play a 
neuroprotective role in neurodegenerative processes.  Many in vitro studies indicate that 
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the addition of estrogen to culture media increases viability, survival, and differentiation 
of primary cultures from different populations, including those from the hypothalamus, 
amygdala, neocortex or hippocampus. The protective effects of estrogens have been 
widely reported in many different neuronal cell types against a variety of toxic insults, 
including oxidative stress (Behl et al., 1995; Borr s et al., 2010; Gordon et al., 2005; 
Morale et al., 2006; Ozacmak and Sayan, 2009; Stirone et al., 2005; Strehlow et al., 
2003), β-amyloid-induced toxicity (Bozzo et al., 2010; Carbonaro et al., 2009; Yang et 
al., 2008; Morinaga et al., 2007; Xu et al., 2006; guado-Llera et al., 2007; Ba et al., 
2004), and excitotoxicity (Behl et al., 1995; Goodman et al., 1996).   The effective 
concentrations for estrogen-mediated neuroprotection range from a low of 0.1 nM to a 
high of 100 µM.  This points to the existence of differences in the sensitivity to estrogen-
mediated protection in different neuronal types.  Additionally, many studies have 
indicated that longer estrogen pretreatment times may increase neuroprotective potency 
of the hormone.  
In addition to the extensive evidence for the neuroprotective effects of estrogens 
in vitro, there is now evidence for the neuroprotective effects of estrogens in animal 
models of the neurodegenerative process. Estrogen exposure yields a reduction in the 
degree of dopamine depletion resulting from treatment with the neurotoxic 6-
hydroxydopamine, a model of PD (Murray et al., 2003; Quesada and Micevych, 2004).  
Moreover, estrogens were also shown to protect nigrostriatal dopaminergic neurons 
against MPTP-induced neurotoxicity in mice model of PD (Ramirez et al., 2003; Callier 
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et al., 2001).  Estrogens also provided neuroprotection against glutamate-induced 
neurotoxicity (Sawada et al, 1998).  
 There are also recent reports that the most frequently prescribed estrogen 
replacement hormones in the United States, conjugated equine estrogens, are 
neuroprotective against neuronal cell death induced by β-amyloid(25-35), hydrogen 
peroxide, and glutamate, and induce neurite outgrowth in cortical, hippocampal, and 
basal forebrain neurons (Diaz-Brinton et al., 2000; Brinton et al., 2000).  This finding 
raised the possibility that estrogen replacement therapy may also have beneficial 
neurotrophic and neuroprotective effects on the brain. 
1.5.2. Potential mechanisms of estrogen neuroprotective actions 
Although, numerous studies demonstrated that estrogens play an important 
trophic and protective role in brain, it is still unclear the precise mechanisms involved in 
the neuroprotective effects of estrogens.  Many of the neuroprotective effects of estrogens 
appear to be mediated by the activation of classical estrogen receptor (ER). Several 
reports have also indicated that estrogen neuroprotective activity is exerted via 
intracellular receptor-mediated mechanisms.  Another plausible mechanism to explain the 
protective effects of estrogens is related to the ability of the hormone to alter free radical 
production or act as an anti-oxidant, which is exerted by their chemical structure. 
1.5.3. Estrogen receptor mediated mechanism of neuroprotection 
The classical mechanism of estrogen action is through one of two estrogen 
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receptors (ERs), ERα and ERβ, which act as nuclear transcription factors.  ERα and ERβ 
each are composed of several domains: a) a highly variable N-terminal domain 
containing a transactivation region that activates expression of target genes by interacting 
with core transcriptional machinery; b) a DNA binding domain that contains two zinc 
fingers and is involved in receptor dimerization and specific DNA binding; and c) a large 
and complex ligand-binding domain that is also involved in nuclear localization, receptor 
dimerization, and interactions with other transcriptional regulatory factors(Witkowska et 
al., 2008; Kuiper et al., 1997).  ERα and ERβ share high sequence homology in their 
DNA and ligand-binding domains (95.5% and 59.7%, respectively, in the rat), but differ 
in other domains(Witkowska et al., 2008; Kuiper et al., 1997; Gruber et al., 2002a). 
When ERs bind estradiol, they can form homo-or heterodimers, which can bind to 
estrogen response elements (EREs) in DNA and recruit other components of transcription 
machinery to promote gene expression(Gruber et al., 2002a). Estradiol-bound ERα and 
ERβ  also bind the Fos/Jun complex to regulate gene expression through activated 
protein-1 sites in a manner that is independent of EREs.  Binding assays indicate that 
estradiol has similar binding affinity for ERα and ERβ.  The two forms of ER are 
structurally and functionally distinct, each regulating unique sets of target genes in a 
tissue and cell type-specific manner (Kian Tee et al., 2004). This may be due to the net 
effect of homo- or heterodimerization of ERβ and ERα.  Receptor-mediated transcription 
is also modulated by coregulators (activator and repressor proteins and protein 
complexes).  The numerous coregulator proteins and various selective combinations 
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associate with ERs and critically determine the region and cell-type specificity of the 
effects of ER ligands. Furthermore, the recent discovery in rodent and human brains of 
ER splice variant proteins, which alter gene transcription in a promoter- and ligand-
dependent fashion, adds further diversity to ER signaling mechanisms (Chung et al., 
2007; Ishunina and Swaab, 2008).  The expression, coexpression, and ratio of ERα/ERβ 
and their splice variants in addition to the presence of combination of coregulatory 
proteins in any cell, will have a profound influence on the estrogen response. 
Steroid hormones have traditionally been thought to act exclusively through 
nuclear receptors (Levin, 2001). However, recently both nuclear and 
membrane/cytoplasmic pools of ERα and ERβ have been demonstrated and the receptors 
have similar affinity for the estrogen ligand. In addition, steroid actions occur at the cell 
surface, a function that is preserved from plants to humans (Levin, 2001; Kushner et al., 
2000).  It is widely accepted that membrane ER signaling through kinase cascades, 
calcium and other second messengers impacts transcription (Watters et al., 2000).  
Pharmacological and ultrastructural evidence demonstrates that classic ERs can also be 
localized at the cell membraneto effect rapid activation of intracellular signaling 
pathways and modulatory proteins  within seconds to minutes of exposure to estrogen 
(McEwen and Alves, 1999; Toran-Allerand et al., 2002; Gorosito et al.,2008; Raz et al., 
2008). These effects include increases in intracellular calcium concentrations and 
activation of protein kinases in the cAMP/camp-dependent protein kinase pathway, the 
mitogen-activated protein kinase (MAPK or ERK), and the PI3K/Akt pathway. These 
pathways may interact and converge, to effect gene transcription and protein synthesis 
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via rapid down-stream activation of transcription factors, such as the CREB or NFκB.  
The mechanisms by which activated membrane ERs elicit cellular responses are 
not yet understood, but interaction with other cell-surface receptors and G-proteins, IGF-
1 and glutamate receptors may be a means in which ERs trigger intracellular signaling 
systems and affect cellular responses (Garcia-Segura et al., 2001, Mermelstein, 2009).  
Estrogen-activated signaling pathways can also increase mitochondrial efficiency and 
lead to a reduction in free radical generation in the brain and mitochondrial dependent 
apoptosis (Nilsen et al., 2007; Brinton, 2008; Chen et al., 2009). Estradiol has been 
reported to act as an NMDA receptor antagonist (Weaver et al., 1997) and to block 
calcium entry through the calcium channel (Mermelstein et al., 1996).  This inhibition of 
calcium entry was not mediated by the estrogen receptor but by a plasma membrane 
receptor for estradiol. It occurs rapidly in seconds after estradiol administration and 
diminished soon after the removal of estradiol. Furthermore, membrane-initiated and 
genomic actions of hormones may be coupled.  Most of the cellular mechanisms 
described for estrogen actions, involving MAPK and PI3K/Akt signaling and 
mitochondrial function, have important roles in cell survival, apoptosis function, 
neurodevelopment, and may subserve the critical neurotrophic and neuroprotective 
effects of estrogens in brain physiology and pathological conditions.   
Protective effects of estradiol could also be mediated by activation of 
mitochondrial ERs, which are present in many cell types, especially tissues such as the 
brain with demand for mitochondrial energy metabolism. Along with nuclear ERs and 
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their coactivators, mitochondrial ERs are involved in cytoprotection from oxidative stress 
and regulation of apoptosis (Razmara et al., 2008). It is suggested that a deficiency in this 
estrogen-dependent mechanism might be related to neurodegenerative disease 
pathogenesis. 
1.5.4. HIV-1 infection in Women 
In recent years, the rate of HIV infection in women has been climbing 
significantly.  HIV infection is the third leading cause of death in women between the 
ages of 25-44y. Women account for half of all people living with HIV worldwide- at the 
end of 2007 and estimated 15.4 million women were infected with HIV (UNAIDS 2008). 
The proportion of women living with HIV varies significantly between different regions 
of the world, with a higher burden in sub-Saharan Africa and the Caribbean.  In sub-
Saharan Africa women account for nearly 61% of all adults living with HIV, while in the 
United States only 25% of people with HIV are women (CDC 2007; UNAIDS 2007). 
Over the last 10 years, the number of women living with HIV globally has remained 
stable, but in latin America, Asia and Eastern Europe this number is slowly increasing 
(UNAIDS 2007).  
HIV-1 infected women have a lower plasma viral load compared to HIV infected 
men at similar stages of HIV-1 infection, suggesting that gender differences may affect 
HIV/AIDS pathogenesis (Sterling et al., 2001; Evans et al., 2001; Farzadegan et al., 
1998).  These differences suggest a higher risk to AIDS among women with lower viral 
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load measurements and significantly lesser eligibility of women for therapy after 
seroconversion according to current guidelines for initiating antiretroviral therapy in 
women (Zhang et al., 2008). Moreover, there is evidence that women are less likely to 
start HAART despite equal access to care (Berg et al, 2004; Gilad et al., 2003).  With 
HIV detected early in the brain after infection, delayed initiation of antiretroviral 
treatment may diminish effectiveness against toxic challenges in the CNS.  Alternate 
therapy, not dependent on viral load, may be considered to circumvent the detrimental 
effects of HIV infection on neuronal functioning and survival. 
 Hormone levels are thought to play an important role in the susceptibility and 
immune responses to HIV-1 infection in women.  In women with HIV infection, 
menstrual abnormalities frequently develop with increased cycle variability, 
polymenorrhea or amenorrhea (Clark et al., 2001; Farzadegan et al., 1998; Harlow et al., 
2000).  Additionally, HIV-infected women have been shown to undergo menopause 
earlier than noninfected women. Perimenopausal and menopausal symptoms may be 
more prevalent among HIV-infected women (Kojic et al., 2007). Conversely, an estrogen 
deficient state such as menopause has been associated with a prolonged disease course, 
and with an increase incidence of AIDS-related dementia. Moreover, a European study 
showed that women are two times more likely to develop HIV dementia than men (Chiesi 
et al, 1996). 
1.5.5. Estrogen in HIV dementia   
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Accumulating evidence suggests that estrogen is able to protect against various 
neurodegenerative insults, including the neurotoxicity of HIV viral proteins.  For 
example, estrogen reduces the extent of cell death in response to a variety of noxious 
disease-related stimuli such as excitatory amino acids (Sribnick et al., 2004), oxidative 
stress (Nilsen, 2008; Wallace et al., 2006) and β-amyloid toxicity (Nilsen et al., 2006; 
Hosoda et al., 2001).  These cellular actions may explain its ability to ameliorate 
cognitive decline and reduce the incidence and progression of neurodegenerative disease.  
Furthermore, estrogen was shown effective in preventing the neuronal damage associated 
with Tat-induced toxicity (Kendall et al., 2005; Wallace et al., 2006). Estradiol protected 
mitochondria in receptor-independent manner that may be related to its anti-oxidant 
properties. Estradiol was also shown to suppress the proinflammatory effects of HIV 
proteins (Bruce-Keller, 2001). 17 β-estradiol treatment was also shown to reduce the 
number of apoptotic neurons and modulate the expression of anti-apoptotic proteins 
including Bcl-2 in primary neuronal cultures (Nilsen et. al., 2006). The mechanism(s) of 
estrogen neuroprotection are not fully understood, but may be linked to regulation of 
proteins that either promote cell survival or induce cell death. Identifying estrogen 
regulated apoptotic factors may be vital to elucidating the underlying mechanism(s) of 
estrogen protection. 
These observations warrant further studies in HIV infected women with cognitive 
impairment or at risk for developing dementia. However, because of the potential risk of 
uterine and breast cancer, estradiol cannot be used in this population. Furthermore, due to 
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feminizing effects of estradiol, it cannot be used in men or children. Hence it is important 
to develop compounds that have the neuroprotective effects of estradiol but not the 
negative side effects. 
 
1.6. Phytoestrogens 
In recent years, phytoestrogens have been attracting increasing attention among 
the public and medical community because of evidence from a large body of literature 
suggesting that consumption of plant-based foods rich in these compounds may benefit 
human health (Than et al., 1998; Adlercreutz and Mazur, 1997; Setchel, 1998).  
Epidemiologic data and clinical experience indicate that estrogen therapy offers 
protection from cardiovascular disease, reduces the extent of osteoporosis, improves 
cognitive function and improves menopausal symptoms associated with ovarian estrogen 
loss.  Substantial data from epidemiologic surveys and nutritional intervention studies in 
humans and animals suggest that dietary phytoestrogens have protective effects against 
menopausal symptoms and a variety of disorders, including neurodegenerative diseases.   
Phytoestrogens are found in various plants consumed by humans, including 
legumes, seeds, and whole grains. Phytoestrogens in the diet may have a role in 
modulating hormone-related diseases based on their structural similarity to 17 β-estradiol. 
The majority of phytoestrogens found in typical human diets can be categorized into two 
primary classess, isoflavones and lignans.  The most abundant food sources of 
 
 
24 
isoflavones are soybeans and its products. Isoflavones are the most common form of 
phytoestrogens. Two of the major isoflavones found in humans are genistein and 
daidzein.  Genistein and daidzein are parent compounds, which are metabolized from 
their plant precursors, biochanin A and formononetin, respectively.  In plants, isoflavones 
are inactive when present in the bound form as glycosides, but when the sugar residue is 
removed, these compounds become activated.  These plant compounds undergo 
fermentation by intestinal microflora, with both metabolites and unfermented parent 
compounds now able to be absorbed. In the body, they do not undergo any further 
metabolism and are excreted in the urine (Sakai et al., 2008).   In the colonic microflora, 
daidzein may be metabolized to equol.  Daidzein, genistein, equol, and O-
demethylangolesin are the major phytoestrogens detected in the blood and urine of 
humans and animals.  
 
The molecular structure of biologically active isoflavones resembles that of 17β-estradiol. 
1.6.1. Absorption and Bioavailability 
 It seems the bioavailability of isoflavones, particularly genistein and daidzein, 
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depends on the gut microflora activity.  Despite considerable degradation of isoflavones 
in the gut, their plasma concentrations are significant.  Isoflavones are mainly present as 
inactive glycosides and after enzymatic processes in the gut by bacteria, they become 
active compounds, taken up by enterocytes and entering the peripheral circulation 
(Branca and Lorenzetti, 2005).  In humans, there is large variability in genistein and 
daidzein metabolism, due in part to variable individual intestinal flora and transit time.  In 
an adult, consumption of 50 mg/day of isoflavones may give rise to plasma 
concentrations ranging from 200-3000 nM.  Other studies evaluating plasma 
concentration of phytoestrogens have reported that plasma levels in humans range from 
10 nM to 10 µM.  
 Numerous factors, such as light, environmental conditions, plant genetics, 
ripeness and species variety, affect the formation and the content of phytoestrogens in 
plants.  It is also reported that the estimated daily intake of isoflavones differs among 
countries, ranging from 20-100 mg/day.  In Asian countries, an average daily dietary 
intake of soy and isoflavones is estimated to 50 g and 20-150 mg, respectively. In 
western countries, intake of isoflavones is considerably lower, at 1g of soy daily and 2mg 
of isoflavones. Also of note, women consuming the commercially available 
phytoestrogen preparations are taking doses ranging from 50-150 mg aglycones/day, 
doses in range of what is consumed in Asian populations. 
1.6.2. Effects of soy isoflavones on cognitive function 
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 Various types of neural damage may induce neurodegenerative diseases 
associated with cognitive decline. Several studies have found that soy isoflavones can 
improve cognitive functions in both humans and rats, but underlying mechanisms remain 
unknown (File et al., 2001). Soy isoflavones have an estrogenic effect and it is reported 
that isoflavones may improve cognitive functions my mimicking the effects of estrogen 
in the brain (Pan et al., 2000).   
Human studies 
 Although numerous experimental studies have shown that isoflavones are 
beneficial to cognitive functioning, in the clinical setting results vary on the cognitive 
effects of isoflavones.  Some studies have shown that isoflavones improve cognitive 
function in postmenopausal women.  The SOPHIA study examined cognitive functioning 
of postmenopausal women receiving soy isoflavones every day over 12 weeks. Women 
receiving soy supplementation showed significantly higher performance on memory and 
attention tasks compared to controls (Duffy et al., 2003;). However another study of  
isoflavone supplementation in postmenopausal women, found no improvement of 
cognitive functioning after 1 year. Additionally, young healthy adults receiving high 
dosage of soy showed significant improvement in short and long-term memory and 
mental flexibility; improvements were seen in both males and females. Although the 
clinical data examining the effects of isoflavones on cognitive function offer differing 
results, these clinical trials indicate that soy isoflavones might improve cognitive function 
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not only in postmenopausal women but also young adult women and males. 
Animal studies 
Several studies have shown that soy isoflavones improve cognitive function in female 
rats. In one study, OVX rats given isoflavone containing diets for 10 months showed a 
dose-dependent improvement in radial arm maze tests (Pan et al., 2000).  Another study 
reported that female rats consuming a lifelong high-isoflavone diet showed acquisition of 
the radial arm maze faster than female rats consuming a isoflavone free diet (Lund  et al., 
2001).  
 The effects of soy isoflavones on cognitive function in male rats remains 
controversial. It is not yet clear whether isoflavones have beneficial or detrimental effects 
on cognitive function in male rats. It has been demonstrated that male rats consuming a 
high isoflavone diet performed worse on a visual spatial memory test than male rats 
consuming an isoflavone-free diet (Lund et al., 2001).  However, it was recently reported 
that male rats consuming an isoflavone diet significantly outperformed  male rats 
consuming a isoflavone free diet in a spatial delayed matching to place test (Lee et al., 
2004).   
1.6.3. Soy Isoflavones neuroprotective effects 
 Several studies have shown that isoflavones have neuroprotective effects against 
various insults.  Genistein has been shown to have an antioxidant effect on neurons 
exposed to radical damage. In human cortical cell lines, pretreatment with 10 or 50µM of 
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genistein was found to prevent cell death due to tertiary butylhydroperoxide or oxidative 
stress (Sonee et al., 2004).  Additionally, in hippocampal cells from rats, genistein was 
found to reverse effects of Aβ25-35 on loss of cell viability, DNA fragmentation, 
intracellular increase in free calcium, the accumulation of reactive oxygen species and 
caspase 3 activation (Zeng et al., 2004).  Another study reported that in thapsigargin-
induced apoptosis, associated with mitochondrial dysfunction, DNA laddering, and 
caspase activation, the addition of genistein was able to decrease the number of apoptotic 
neurons and the number of neurons containing active caspase-3 (Linford and Dorsa, 
2002).  Genistein was also found to protect human neuroblastoma cells from Aβ-induced 
death and attenuated Aβ-induced apoptosis (Bang et al., 2004). Moreover genistein and 
daidzein were among six phytoestrogens that demonstrated neuroprotective efficacy 
against glutamate excitotoxicity and Aβ25-35 in hippocampal neurons (Zhao et al., 2002).   
1.6.4. Potential mechanisms of soy isoflavones actions in the brain  
Estrogen receptor-mediated regulation 
17β-estradiol, a mammalian estrogen, has been shown to protect neurons and affect 
cognitive function.  It is thought that this effect is associated with estrogen receptors 
(ERs) in the brain, additionally is also suggested that isoflavones had neuroprotective and 
cognitive functions in the brain.  Estrogen has been shown to affect neuron survival and 
growth, synaptic plasticity, brain function via a ER-mediated pathway and/or antioxidant 
properties. The effects of estrogen on nuclear and nonnuclear ERs can modulate brain 
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functions by regulating gene transcription and second messenger systems. Isoflavones 
may act in a similar way because they too exhibit estrogenic activity.  
 The estrogen effects of isoflavones appear to be dose dependent. Some studies 
suggest that the neuroprotective effects of isoflavones may be mediated by two 
mechanisms that operate at different concentrations.  These studies demonstrate that at 
the nanomolar level, genistein protects neurons via an ER-mediated pathway, while at the 
micromolar level, genistein displays antioxidant abilities (Zeng et al., 2004).   
 As isoflavones can affect the viability of neurons and cognitive function by acting 
as estrogenic agonist, they can also utilize differential distribution and regulation of the 
ER subtypes, ERα and ERβ in the brain.  The binding affinity for ERβ is higher than that 
for ERα by a factor of 20-fold in vitro.  Additionally, genistein has been shown to affect 
ERβ- but not ERα-dependent gene expression in the hypothalamus. However, it is still 
unclear which ER subtype mediates the neuroprotective efficacy of 
estrogen/phytoestrogen. Treatment with 17β-estradiol prevented the apoptotic neuron 
death, and resulted in the strong expression of ERα and increased bcl-2 in primary 
cultures from rat brain (Harms et al., 2001). Several lines of evidence also suggest that 
ERβ is involved in neuroprotection.  Estradiol exerted neuroprotective effects on 
dopaminergic neurons by suppressing proapoptotic gene transcription through the AP-1 
site via activation of ERβ (Sawada et al., 1998).  Genistein was also shown to attenuate 
neuronal apoptosis via an ERβ-mediated pathway.  In this study, only ERβ was detected 
in a neuron culture, thus it was suggested that the neuroprotective effect of isoflavone is 
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mediated through ERβ.  However, there have been reports that demonstrated that both ER 
subtypes are involved in neuroprotective actions.  Both ERα and ERβ agonists were 
found to protect hippocampal neurons from glutamate-induced neurotoxicity (Zhao et al., 
2004).   
  Like estradiol, phytoestrogens are thought to have neuroprotective effects due to 
the ability to bind estrogen receptors and mediate estrogenic processes. Phytoestrogen 
preferential binding to ERβ is of significant consideration in neuroprotection as this ER 
subtype is highly expressed in the brain compared to ERα, which due to its high 
expression in the reproductive tissue, has been associated with the proliferative effects of 
estrogen. Elucidating whether phytoestrogen neuroprotection is mediated by ER 
selectivity is a central focus in research of neurodegenerative diseases.  
Summary 
Neuronal injury is a primary basis of many neurodegenerative diseases, including HIV-1 
associated dementia (HAD). The HIV-1 viral protein Tat is thought to play a significant 
role in HIV related neuropathology and involving mitochondrial dysfunction and the 
potentiation of neuronal apoptosis.  Hormone levels are thought to play an important role 
in the susceptibility and immune responses to HIV-1 infection in women. Estrogen 
deficiency has been associated with increased risk of neurodegenerative disease, 
including HAD. Accumulating evidence suggests that estrogen is able to protect against 
various neurodegenerative insults, which are mediated by two estrogen receptor (ER) 
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isoforms, ERα and ERβ. Despite its positive actions, the benefits of estrogen therapy on 
women’s health are overshadowed by its association with an increased risk of 
reproductive cancers and cardiovascular disease. However, soy phytoestrogens represent 
a viable alternative to estrogen therapy as they have been shown to bind to ERs and affect 
estrogen mediated processes. In the current experiments, we seek to determine if 
treatment with 17 β-estradiol attenuates HIV-1 Tat-induced mitochondria associated 
apoptotsis in cortical cell cultures;  whether estrogenic effects against Tat –induced 
mitochondria mediated apoptosis occurs through receptor mechanisms; and lastly, if 
phytoestrogens are equally effective as endogenous estrogen 17 β-estradiol against Tat-
induced apoptotic signaling. We proposed that estrogen neuroprotection against HIV-1 
viral protein Tat-induced neural toxicity involves ER-mediated attenuation of apoptotic 
signaling. Furthermore, soy phytoestrogens can mimic estrogen effects against Tat-
induced apoptosis by targeting ER-subtype specific effects. 
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Mitochondria-mediated apoptotic cascade. HIV-1 Tat exposure (red arrows) has been 
shown to induce mediators of the apoptotic cascade leading to subsequent cell death.  
However, the antiapoptotic effects of estrogen (blue arrows) has been shown to involve 
regulation of Bcl-2- related proteins and downregulation of  caspase activity.  
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CHAPTER 2 
Experiment 1. To determine 17 β-estradiol effects on HIV-1 Tat –induced apoptotic 
signaling in primary cortical cell cultures.  
2.1. Introduction 
  Estradiol is known to have protective properties for neural cells during injury and 
chronic diseases including neuro-AIDS (Nilson, S. et al., 2001; Wilson et al, 2006). It 
reduces the extent of cell death in response to variety of noxious stimuli such as 
excitatory amino acids, oxidative stress and β-amyloid toxicity by both in vitro and in 
vivo methods (Behl, 2002).    Furthermore, estrogen was shown effective in preventing 
the neuronal damage associated with Tat-induced toxicity (Turchan et al., 2001; Kendall 
et al., 2005; Wallace et al., 2006). Estradiol treatment was also shown to reduce the 
number of apoptotic neurons and regulate the expression of anti-apoptotic proteins 
including Bcl-2 in primary neuronal cultures (Nilsen et. al., 2006). Studies have also 
shown that estrogen administration was able to attenuate caspase activation, which is 
responsible for many of the biological and morphological features of apoptosis, and 
mitochondrial signal transduction pathways induced by neurotoxic insults (Zhang et al., 
2005). These cellular actions may explain its ability to ameliorate cognitive decline and 
reduce progression of neurodegenerative disease. As mitochondria play a central role in 
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apoptosis and neurodegeneration, we will further assess if Tat exposure induces 
mitochondria mediated apoptotic cell death. We will determine if the addition 17 β-
estradiol prior to Tat exposure attenuates Tat-induced cell death signaling.  
2.2. Experimental Design 
 Recombinant Tat 1-86 (50 nM) (Diatheva, Italy) was added to culture medium. To assess 
neurotoxicity, cortical cell cultures were exposed to Tat for 4, 24, 48, or 72 h for cell 
viability assays. In assessing estrogen effects against Tat toxicity, 17 β-estradiol (10 nM, 
Sigma) was added to neuronal culture 24 h prior to Tat exposure. Tat induction of 
apoptotic pathway was assessed by total caspase activity using FLICA in live Tat 
exposed cultures. A direct interaction of Tat and apoptotic neurons was determined via 
immunocytochemisty using antibodies against Tat and active caspase 3.  Enzyme -linked 
immunosorbent assay (ELISA) was used to quantify expression of mitochondria 
apoptotic pathway regulatory proteins, pro- and anti-apoptotic Bcl-2 family proteins Bax 
and Bcl-2 respectively and active caspases in fetal rat cortical cultures exposed to Tat. 
We determined if Tat exposure increases expression of mitochondrial apoptotic markers 
Bax, Bcl-2 and caspase 9 and caspase 3, and whether estrogen effects on Tat-induced cell 
death involve attenuation of the mitochondria mediated apoptotic cascade. Data was 
analyzed with a one way ANOVA and planned comparison tests.   
2.3. Materials and Methods 
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2.3.1. Cortical cell culture  
Neuronal cultures were prepared from 18-day-old Sprague-Dawley rat fetuses.  Rat  
cortex were dissected and incubated for 15 min in a solution of 2 mg/ml trypsin in Ca
2+
  
and Mg2+ - free hanks balanced salt solution (HBSS) buffered with 10 mM HEPES 
(Invitrogen, Carlsbad, CA). The tissue was then exposed for 2 min to soybean trypsin 
inhibitor and rinsed three times with HBSS.  Cells were dissociated by trituration and 
distributed to poly-L-lysine coated culture plates.  At the time of plating each well 
contained DMEM/F12 medium supplemented with 100 ml/l fetal bovine serum. After a 
24 h period, the DMEM/F12 medium was replaced with 2% v/v B-27 Neurobasal 
medium supplemented with 2 mM GlutaMax and 0.5% w/v D- (+) glucose.  Cultures 
were used for experiments after 12 days in culture. 
2.3.2. Cell Viability  
Neuronal survival was determined using a Live/Dead viability/cytotoxicity kit (Molecular 
Probes, Eugene, OR) in rat fetal cortical cell cultures prepared in 96-well plates. In 
accordance with the manufacturer's protocol, neurons were exposed to cell-permeant 
calcein AM (2 μM), which is hydrolyzed by intracellular esterases, and to ethidium 
homodimer-1 (4 μM), which binds to nucleic acids. The cleavage product of calcein AM 
produces a green fluorescence (F530 nm) when exposed to 494-nm light and is used to 
identify live cells. Bound ethidium homodimer-1 produces a red fluorescence (F645 nm) 
when exposed to 528-nm light, allowing the identification of dead cells. Fluorescence 
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was measured using a Bio-Tek Synergy HT microplate reader (Bio-Tek Instruments, Inc., 
Winooski, VT). Each individual F530 nm and F645 nm value on a plate was corrected for 
background fluorescence (readings obtained from cell cultures (wells) that were not 
exposed to calcein AM and ethidium bromide) by the microplate reader KC4 software 
package (Bio-Tek Instruments, Inc., Winooski, VT). For each individual cell culture 
(well) on a plate, ratios between corrected green and red fluorescence (F530 nm/F645 nm, 
Live/Dead ratios) were calculated. All individual relative numbers of live and dead cells 
were expressed in terms of percentages of average maximum Live/Dead ratio determined 
for the set of non-treated control cell cultures (8–16 wells) from the same plate: 
[F530 nm/F645 nm]well n/[F530 nm/F645 nm]average max × 100%. 
2.3.3. Apoptosis detection 
Following Tat treatment, neuronal apoptosis was analyzed by the Fluorochrome Inhibitor 
of Caspases (FLICA) Poly-Caspase (green fluorescence) Apoptosis Detection Kit 
(Immunochemistry Technologies LLC, Bloomington, MN). Poly-caspases Detection Kit 
contains a carboxyfluoroscein-labeled inhibitor of total caspase activity (CR-VAD-
fluoromethyl ketone). VAD is an amino acid sequence targeted by all caspases. When 
covalently coupled to caspases, the dye is retained within the cell and the fluorescent 
signal is a direct measure of the number of active caspase enzymes that were present in 
the cell at the time the reagent was added. FLICA solution was added directly to the cell 
incubation medium and the plate was returned to the incubator for 1 additional hour.  
After 1h, Hoechst stain was added to the medium for neuronal nuclei 
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counterstaining and incubated for an additional 3-5 min at 37°C.  Cells were washed 
twice with wash buffer supplemented with the kit. For the microplate readings of total 
caspase activity, rat fetal cell cultures were prepared in black wall 96-well culture plates 
(Costar). Green fluorescence produced as a result of interaction of CR-VAD fluoromethyl 
ketone with active caspases in Tat-treated and control cultures was determined using 
488/530 nm filter set. Sensitivity was automatically adjusted to low signal wells that 
contained no fluorescent inhibitor. Blue fluorescent Hoechst neuronal nuclei counterstain 
was used to normalize differences in cell density between individual wells.   
2.3.4. Immunocytochemistry                                                                                                                
For immunocytochemistry experiments,  Tat-treated cultures and non-treated controls 
were fixed in acetic alcohol (95% ethanol, 5% acetic acid) for 10 min and washed three 
times (5 min/wash) with Dulbecco phosphate-buffered saline (D-PBS): Na2HPO4 
(1150mg/L), KH2PO4 (200 mg/L), NaCl (8000 mg/L), KCl (200mg/L) at pH 7.4. 
Following fixation, cultures were blocked with 10% normal horse serum (NHS) in PBS 
and used for the analysis. 
2.3.5. Anti-Tat and active caspase immunofluorescence 
Rabbit polyclonal Tat antibody (Diatheva, Italy) was used to determine Tat 1-86 
immunoreactivity. Mouse monoclonal active caspase 3 antibody was used to determine 
caspase 3 activity.  Primary antibodies were diluted 1:500 in 1% NHS/PBS.  Cell cultures 
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were incubated with primary antibodies overnight at 4°C. Each set of experiments 
included cell culture dishes which were left without primary antibody.  These cell 
cultures served as controls for non-specific binding of secondary antibodies.  After 
incubation with primary antibodies was complete, plates were washed three times 
(5min/wash) with PBS. For the immunofluorescent detection of Tat immunoreactivity 
goat anti-rabbit IgG conjugated with Alexa 594 dye (Molecular Probes) diluted 1:500 in 
1% NHS/PBS was used. Plates were incubated with secondary antibodies for 1h at room 
temperature and then washed 3 times with PBS. 
Microscopic images of Tat and active caspase 3 immunoreactivity in primary cell 
cultures were captured using the computer-controlled inverted fluorescent microscope 
(Nikon Eclipse TE2000-E) under 20x magnification and analyzed using NIS-Elements 
BR 2.30 imaging software package (Nikon). Images of specific Tat immunofluorescence 
were merged with the subsequent differential interference contrast (DIC) images.   
2.3.6. Detection of apoptotic proteins (ELISA) 
Cortical cell cultures were prepared as described previously. 17 β-estradiol (10 nM, 
Sigma) was added to neuronal cell cultures 24 h prior to Tat exposure. After 24h estrogen 
pretreatment, recombinant Tat 1-86 (50 nM, Diatheva, Italy) was added to culture 
medium. Cell cultures were then exposed to Tat for 4, 16, and 24h before cell harvesting 
for ELISA experiments. Cell lysates were prepared from cultures grown in 24-well 
plates. At the time of harvesting, medium was removed and cells were washed three 
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times with Dulbecco phosphate-buffered saline, D-PBS, (8 mM Na2HPO4, 1.5 mM 
KH2PO4, 0.137 M NaCl and 2.7 mM KCL at pH 7.4) and lysed with CellLytic 
TM
- M 
mammalian cell lysis buffer (Sigma Chemicals) containing protease inhibitors (protease 
inhibitors cocktail, Sigma Chemicals). All samples in a group (6 sister culture wells) 
were pooled together and protein concentration was determined by BCA method (Pierce, 
Rockford, Ill.).  Each well of Costar 96-well ELISA plates (Corning Inc, PA) was coated 
overnight at 4 °C using 100 μl of 20 mM carbonate coating buffer, pH 9.6. Cell culture 
lysates were diluted 1:10 with D-PBS and 2 ug of each sample were added to the plate 
wells in triplicates. After overnight incubation at 4 °C, plates were rinsed 5 times with 
PBST (0.05% Tween 20 in PBS, pH = 7.4) and blocked with 1% BSA in PBS for 2 h at 
room temperature. After blocking, plates were washed again as described above and 
primary anti-Bax, anti-Bcl-2, anti- active Caspase 9 and anti- active Caspase 3 antibodies 
(Abcam, Cambridge, MA) diluted 1:5000 in 0.1% BSA-PBST were added to each well 
except for blanks and no-primary antibody control wells. Plates were kept overnight at 
4 °C. When the incubation with primary antibodies was completed, plates were again 
washed 5 times with PBST and secondary antibodies (goat anti-rabbit alkaline 
phosphatase conjugated, Sigma) diluted 1: 2000 in 0.1% BSA-PBST were added to each 
well except for blank and no-secondary antibody control wells. After 2 h of incubation, 
secondary antibody solution was removed, plates were washed 5 times with PBST and 
100 μl of BluePhos phosphatase substrate mixture (KPL Research, Gaithersburg, MD) 
was added to the plate wells. After 30 min of incubation, the absorbance at 650 nm was 
determined using a Bio-Tek Synergy HT microplate reader. Multiple readings were taken 
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within a 1-h time period.  
2.4. Statistical Analysis 
Statistical comparisons were made using one way ANOVA and Tukey’s multiple 
comparison tests were used to determine specific treatment effects. Significant 
differences were set at p<0.05.  Data represent percent of control values.  
 
2.5. Results 
2.5.1. Estrogen delays cell viability changes in primary neuronal cultures exposed to Tat 
1-86  
Previous studies have demonstrated that 17 β-estradiol was protective against 
neurotoxicity induced by HIV-1 viral proteins in cell culture (Kendall et al., 2005; 
Turchan et al., 2001), specifically using Tat 1-72.  We evaluated the ability of 17β-
estradiol to protect against recombinant HIV Tat1-86 -induced toxicity,the more stable tat 
variant, derived from the first and second exons of the tat gene.  Preliminary dose 
response studies demonstrated no significant differences in protective efficacy of doses 
ranging from 10 nM-100 nM of 17β-estradiol.  Additionally, prior studies have shown 
that 10nM dose of 17 β-estradiol was effective against HIV protein toxic insults in vitro 
(Kendall et al., 2005).  Significant decreases in cell viability were detected in Tat-treated 
cultures after 48h and 72h, p<0.05. Pre-incubation with 10 nM 17 β-estradiol attenuated 
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the neurotoxic effects of HIV Tat 1-86 (Figure 2.1). Treatment with estradiol prevented 
the 20% reduction in cell viability observed in cultures treated with Tat alone.  Repeated 
measures ANOVA revealed significant main effects of time [F(3,27)=29.65, p<0.05] and  
treatment [F(1,9)=7.69, p<0.05] and a significant time and treatment interaction 
[F(3,27)=7.41, p<0.05]. Specifically, 17 β-estradiol was effective in delaying the onset of 
Tat-induced cell death, as a significant difference in cell viability between Tat-treated vs. 
Tat + 17 β-estradiol cultures was detected at 48h and 72h, p<0.05.  
2.5.2. Caspase activation in rat primary neuronal cell cultures exposed to Tat1-86 
 Execution of the apoptotic pathway leading to DNA degradation, subsequent cell 
death, involves activation of the caspase cascade.  Results of microplate fluorescent 
detection of total caspase activity in cell cultures exposed to 50nM dose of Tat 1-86 for 2, 
24, and 48 h are shown in Figure 2.2A.  Significant increases in total caspase activity 
were detected in cell cultures exposed to Tat for 2h (127±11%, p<0.05) and 24 h 
(145±8.4, p<0.05).  In cell cultures treated with 50 nM Tat for 48 h or longer, total 
caspase activity was not different from controls.  
2.5.3. Tat immunoreactivity colocalize with active caspase expression in neuronal culture 
We determined if Tat induction of cell death involves direct interaction of Tat 
with apoptotic neurons.  Figure 2.2B demonstrates the immunodetection of cell-bound 
Tat immunoreactivity and active caspase 3 immunoreactivity in neuronal cultures 
exposed to 50 nM Tat for 2h.  These results indicate the colocalization of bound Tat 1-86 
 
 
42 
with activated caspases in cultured neurons.  
2.5.4. HIV/Tat exposure increases Bax, Bcl-2, and caspase activation in neuronal culture  
Prior experiments have demonstrated that Tat treatment induced apoptosis in 
primary cell cultures (Aksenova et al., 2009; Bonavia et al., 2001).    This Tat induced 
apoptosis may involve activation of the mitochondrial mediated apoptotic pathway. 
Therefore, we assessed markers specific to the mitochondrial apoptotic pathway 
including active caspase expression and pro- and anti-apoptotic proteins, Bax and Bcl-2 
at different time points following exposure to 50nM Tat 1-86 (Figure 2.3). Results 
indicate that active initiator caspase 9 protein levels were significantly increased early 
(4h) after Tat exposure (122±9%, p<0.05); levels at later time points decreased and were 
not significantly different from untreated controls. Tat also induced a significant increase 
in active caspase 3 expression early (4h) (208 ± 9%, p<0.05) after treatment, and this 
increase was maintained throughout later time points, 16h (187± 7%, p<0.05) and 24h 
(211±7, p<0.05).  
We also observed the expression of upstream apoptotic regulatory proteins Bcl-2 
and Bax, which monitor mitochondrial membrane permeability and thus the release of 
apoptotic factors from mitochondria involved in caspase activation. Results indicated that 
Tat treatment caused a ~60% increase in pro-apoptotic Bax expression at 4h (p<0.05) 
that was maintained until 16h of exposure (p< 0.05) (Figure 2.3). Additionally, anti-
apoptotic Bcl-2 protein levels reached significantly high levels only after 16h of Tat 
exposure (147±10%, p<0.05). No significant changes were seen at 4h or 24h of Tat 
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exposure, as levels were similar to that of controls.   
2.5.5. 17 β-estradiol attenuates Tat-induced expression of Bcl-2, Bax and active caspases 
in neuronal cultures 
We examined the effects of 17β-estradiol against Tat –induced Bcl-2 and Bax 
protein expression.  Our findings demonstrate that pretreatment with estrogen caused a 
significant reduction in Tat-induced expression of Bax vs. cultures treated with Tat alone 
(83 ± 4% vs. 131±8%, p<0.001) (Figure 2.4A). Addition of 17 β-estradiol completely 
reversed Tat-induced changes in Bax, as exhibited by an approximately 45% reduction in 
Bax protein levels, relative to those generated by Tat alone.  Results indicated that 
estrogen administration attenuated the Tat-induced increase in Bcl-2 observed at 16h of 
exposure (Figure 2.4B). Compared to cultures treated with Tat alone, cultures treated 
with estradiol (10nM) 24h before Tat exposure displayed a significant 20% decrease in 
Bcl-2 expression (103±7% vs. 123±7% tat-treated cultures, P < 0.05).  
 Caspase activation is known to be a critical phase in the cell death process.  
Activation of initiator caspases, such as caspase 9 leads to the further activation of 
effector caspase 3, which triggers the final proteolytic phase of apoptosis (Green, 1998; 
Haeberlein, 2004; Spierings et al., 2005).   We examined if the addition of estradiol could 
eliminate Tat-induced increases in active caspase 9 and active caspase 3 expression.  
Results indicated that pretreatment with 10nM 17 β-estradiol significantly attenuated 
early (4h) Tat-induced caspase 9 expression (p<0.05) (Figure 2.5A). We then determined 
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if the inhibition of Tat-mediated caspase 9 activation by estrogen corresponded with 
reduced active caspase 3 immunoreactivity. Our results show that estrogen treated 
cultures displayed modest though significant attenuation of caspase 3 expression at 4h 
(141±4 vs. 166±8 tat-treated cultures, p<0.05), 16h (130±4 vs. 159 tat-treated cultures, 
p<0.05) and 24h (136±4 vs. 160±5 tat-treated cultures, p<0.05) (Figure 2.5B). However, 
estrogen down regulation of caspase 3 was not complete to the level of untreated 
controls. 
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Figure 2.1 Estrogen treatment delays HIV-1 Tat 1-86 mediated decrease of cell 
viability in primary rat cortical cultures.  The graph demonstrates the decrease in live 
cells in primary cultures following exposure to 50 nM Tat 1-86. Addition of 10nM 17β-
estradiol 24h prior to Tat 1-86 exposure was able to significantly delay onset of cell death 
in primary neuronal cultures.  Data presented as mean values, n of sister cultures 
analyzed 5-10 per each time point. *p<0.05 as compared to non-treated controls, 
#p<0.05 as compared to Tat-treated vs. Tat+E treated cultures. 
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Figure 2.2. Caspase activity in rat fetal cortical cultures exposed to 50nM Tat1-86. 
(A). Time course of total caspase activity in cortical cell cultures continuously exposed to 
50 nM Tat 1-86. Data presented as mean values±SEM, n of sister cultures analyzed 7-12 
per each time point. *p<0.05 (B). Microscopic image of Tat immunoreactivity (red 
fluorescence) and active caspase 3 (green fluorescence) immunoreactivity in primary 
cortical cultures treated for 2h with Tat.  
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Figure 2.3. Time course of apoptotic protein expression following Tat exposure. 
Cortical lysates were collected at 4h, 16h and 24h following Tat 1-86 (50 nM) exposure.  
Expression of Bcl-2 (anti-apoptotic), Bax (pro-apoptotic), active Caspase 9 (initiator) and 
active Caspase 3 (effector) were assessed by ELISA experiments. Results are presented 
as % of control values, experiments performed in triplicate, *p< 0.05 as compared to 
controls. 
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Figure 2.4. 17β-estradiol attenuates Tat-induced expression of Bcl-2 and Bax protein 
levels.  Cortical cultures were treated with 10 nM 17β-estradiol 24h prior to Tat exposure. 
Expression of apoptotic proteins A. Bax (4h Tat exposure) and B. Bcl-2 (16h of Tat 
exposure) were assessed by ELISA experiments. Results are presented as % of control 
value, with experiments performed in triplicate, *p<0.05 as compared to controls, **p< 
0.05 as compared to Tat-treated cultures. Legend box: Tat (T), Tat+Estrogen (T/E). 
Reference line in graph represents control group. 
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Figure 2.5. 17β-estradiol attenuates Tat-induced increases in active caspase 
expression Cortical cultures were treated with 10 nM 17β-estradiol 24h prior to Tat 
exposure. Expression of active A. Caspase 9 (4 h of Tat exposure) and B. Caspase 3 were 
assessed by ELISA experiments. Results are presented as % of control value, with 
experiments performed in triplicate, *p<0.05 as compared to controls, **p< 0.05 as 
compared to Tat-treated cultures. Legend box: Tat (T), Tat+Estrogen (T/E). Reference 
line in graph represents control group. 
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2.6. Discussion 
The neuroprotective actions of estrogen have been demonstrated in many 
experimental models of neurodegenerative disease, including various dementias (Pike et 
al., 2009; Wilson et al., 2006).  However, the mechanisms underlying the beneficial 
effect of estrogen are not well understood (Green & Simpkins, 2000).  In this study, we 
sought to determine if estrogen attenuates Tat-induced cell death by inhibiting caspase 
cascade activation and modulating levels of anti-apoptotic and pro-apoptotic Bcl-2 
related proteins, key regulators of mitochondrial/intrinsic apoptotic signaling.   
Extensive cortical neuron damage and dropout is a significant consequence of 
NeuroAIDS, likely stemming from susceptibility of cortical cells to the various toxic 
mechanisms attributed to HIV-1 viral infection, contributed by the protein Tat. Tat may 
play a role in HIV-1 related neuropathology as prior studies have demonstrated the 
presence of Tat mRNA and protein in patients with HIVE and HAD. AIDS dementia is 
characterized by neuronal loss associated with synaptic damage (Weiss et al., 1999) and 
Tat exposure in vitro has been shown to induce similar pathology (Kim et al., 2008). As 
HIV-infected individuals are living longer, the rate of CNS disease is actually increasing, 
as well as the incidence of cognitive impairment, intensifying the need for therapeutic 
interventions capable of supporting neuronal functioning and viability.  
In the present study , we used primary fetal rat cortical cell cultures to 
demonstrate that HIV- 1 Tat 1-86 can induce neuronal cell death by apoptotic 
mechanisms and that the process can be reversed or inhibited by 17β-estradiol. Our 
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results demonstrate that Tat exposure induced delayed cell death, as significant decrease 
in cell viability does not become apparent until 48h of Tat exposure. This suggests that in 
Tat-induced cell death, susceptible neurons are primed for death. Previous studies in our 
lab and others, demonstrate that Tat is rapidly taken up into cells with maximal 
absorption/binding detected at 2hr of Tat exposure. This coincides with our findings of 
increased ROS production and a decrease of mitochondrial membrane potential, and 
activation of caspases early (2h) after Tat exposure. These observations indicate that Tat 
initiate toxic events that primes susceptible neurons for cell death.  
Estrogen pretreatment significantly attenuated Tat-induced cell death, thus it is 
plausible that estrogen effect on cell death involves attenuation of Tat neurotoxic 
mechanism(s).  The delay in cell death represents a critical window of opportunity for 
therapeutic intervention to augment Tat-induced cell death. Understanding the toxic 
challenges associated with Tat exposure essential to preventing subsequent loss of cell 
viability and function.  Although HIV-1 Tat has been shown to be neurotoxic, 
information about the time course of the development of Tat-mediated neurodegeneration 
is very limited. Direct interactions of Tat with cultured neurons, which includes binding 
of Tat to neuronal cell membrane, the uptake of the protein and translocation of Tat into 
the nuclei, require a very brief exposure time (Chandra et al., 2005; Aksenova et al., 
2009).  Studies in our lab demonstrate that the absorption of Tat by rat fetal neurons 
occurs within min after the addition of Tat to the culture medium. Previously, we 
reported increased ROS production and mitochondrial dysfunction following 2h exposure 
cell cultures to 50nM Tat 1-72 (Aksenov et al.,2006).  In the current experiment we 
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demonstrate an increase in total caspase activity in 2hr of Tat exposure that was 
maintained over 24h.  Levels of active caspases returned to that of controls by 48h.  The 
loss of caspase activity coincides with significant decrease of cell viability, implicating 
that the dead neurons were expressing active caspases. As neurons are dying, caspase 
activity is loss. 
Indeed the time period during which Tat 1-86 immunoreactivity is detectable in 
cell lysates overlaps with the increase in early and total caspase activities. Moreover, 
immunocytochemistry experiments detecting Tat and caspase 3 immunoreactivity 
demonstrate the colocalization of bound/internalized Tat with activated caspases in 
neurons.  These observations confirm the theory that direct interactions of Tat induce 
oxidative stress-dependent apoptosis in neurons (Kruman et al., 1998; Aksenov et al., 
2006; Aksenova et al., 2009).  
Additionally, we determined that Tat –induced cell death was mediated by 
activation of caspases, a family of enzymes involved in signal transduction of apoptotic 
stimuli and cellular disassembly (Stennicke and Salvesen, 2000).  Caspase 3, the 
downstream effector of the caspase cascade, is activated in several neurodegenerative 
disorders (Garden et al., 2002, Namura et al., 1998; Su et al, 2000).  Elevated active 
caspase 3 immunoreactivity was reported in cerebrocortical neurons from patients with 
HAD and in cultured rodent neurons exposed to HIV viral proteins (Zheng et al., 1999). 
Our results demonstrate that active caspase 3 expression was significantly increased early 
following Tat exposure and these elevated levels were maintained for 24h after Tat 
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exposure. These findings support our findings that detected increases in total activated 
caspases in living cells and demonstrated increases in total caspase activity early after Tat 
exposure, peaking at 24h (Aksenov et al., 2009).   
Previous studies have shown that the neurotoxic capabilities of Tat include 
inducing oxidative stress and disrupting mitochondrial membrane functioning (Aksenov 
et al., 2006; Aksenova et al., 2006; Kruman et al., 1998). Moreover, the mitochondria 
play a central role in mediating apoptotic signaling (Kroemer et al., 2007; Danial 
&Korsmeyer, 2004; Green& Kroemer, 2004:1998). As such, we determined if Tat-
induced caspase 3 activation corresponds with the expression of key regulatory proteins 
linked to mitochondria mediated apoptotic pathway in cultured cortical neurons.  
Following the addition of Tat 1-86 to primary cultures, increased expression of active 
caspase 9, an initiator caspase associated with mitochondria-mediated apoptosis pathway, 
was apparent after 4h of Tat exposure.  The activation of caspase 9 was detected as early 
as 2h following Tat treatment in living cells (Aksenova et al., 2009). However, active 
caspase 8 immunoreactivity, associated with extrinsic/death receptor mediated apoptotic 
cell death was not detected in Tat exposed cortical cultures (data not shown).  Lack of 
caspase 8 activation in Tat treated cultures suggests that the death- receptor initiated 
apoptotic cascade may not play a major role in our model of Tat -induced caspase-
dependent apoptosis.   
Consistent with the suggestion that mitochondrial intrinsic pathway contributes to 
Tat-mediated apoptosis, our results demonstrated that pro-apoptotic Bax protein levels 
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were significantly increased early after the addition of Tat 1-86 to neuronal cultures. This 
increase in Bax expression was concurrent with expression of active caspases. Moreover, 
in our culture model, a ~20-30% reduction in cell viability with Tat exposure has been 
observed (Aksenova et al., 2009). Even with prolonged exposure and with Tat 
maintaining its toxicity, only a particular population of neurons appeared to be Tat-
sensitive and die, whereas the remaining cells were resistant to Tat-toxicity. We observe 
that rat fetal neuronal cell cultures contain a subpopulation of neurons in which Tat 
interactions are able to induce a caspase-dependent apoptotic cascade. It is likely that the 
early induction of pro-apoptotic signals (Bax, caspase activation) may increase the 
susceptibility of Tat-sensitive cells to cell death. However, we found that an increase in 
anti-apoptotic protein Bcl-2 followed this induction of Bax expression and caspase 
activation. The significant increase in Bcl-2 expression may mediate a neuronal survival 
promoting response and thus reflect a compensatory mechanism to impede further 
apoptotic signaling and maintain the viability of remaining neurons. 
  Although Tat-induced apoptosis has been associated with caspase activation 
(Kruman et al., 1998), alternate mechanisms of cell death may also be activated by Tat 
toxicity. Caspase-independent apoptosis is well established and suggest the induction of 
alternate execution pathways. NMDA receptors are known to play the key role in the 
mechanism of Tat-mediated apoptosis (Haughey et al., 2001; Perez et al., 2001; Eugenin 
et al., 2007; Kim et al., 2008; Aksenova et al., 2009).  Activation of NMDA receptors led 
to the development of apoptosis without involvement of caspases, due to the direct action 
of apoptosis-inducing factor (AIF) on neuron nuclei (Evstratova et al., 2009). This 
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mechanism involves the release of AIF, which is translocated from the mitochondrial 
membrane to the nucleus, inducing DNA degradation.  
Estrogen deficient states may partly account for declines in cognition and 
neurodegeneration that are associated with dementia, such as HAD. The current 
experiments show estrogen treatment was able to delay the onset of cell death by 
attenuating Tat- induced apoptotic signaling.  Upstream of caspase activation, we also 
show that Tat- induced increases in expression of Bcl-2 and Bax was reversed by 
estrogen.  Since the Bcl-2 related proteins are made up of a group of apoptosis regulatory 
genes of which Bcl-2 is anti-apoptotic and Bax is pro-apoptotic, the ratio of Bcl-2 to Bax 
may determine whether the cells undergo apoptotic cell death or survive the toxic insult.   
Perhaps a key mechanism by which estrogens augment apoptotic signaling in Tat-
induced cell death is by altering this ratio in favor of anti-apoptotic proteins (Zhang et al., 
2003).  The significant down regulation of proapoptotic protein Bax by estrogen could 
serve to balance this ratio and normalize mitochondrial function, preventing the release of 
apoptotic factors and initiation of the caspase cascade.  This estrogen effect on Bax along 
with its effects on Bcl-2 and caspases serves to prolong the compensatory/survival 
promoting response of cells which corresponds with the significant delay of apoptotic cell 
death observed with estrogen treatment.   
The current experiments show that upregulation of caspases and Bax, Bcl2 
expression precede cell death, supporting the observation that Tat-induced cell death was 
the consequence of activation on the mitochondria-mediated apoptosis pathway.  
Furthermore, our observations indicate that estrogen protects against Tat-induced 
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apoptosis in primary cortical cultures in part by inhibiting caspase-activation and 
preventing mitochondrial membrane permeability.   
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CHAPTER 3 
Experiment 2. To determine whether estrogen affects Tat-induced apoptosis 
through estrogen receptor- mediated mechanisms 
3.1. Introduction 
 Estrogens regulate the expression of a number of target genes by binding the 
estrogen receptors ERα and ERβ, which function as ligand-activated transcription factors 
(Jover et al., 2002; Morrisette et al., 2008). However, there is still debate about which 
receptor subtype mediates the protective actions of estrogen (Dubal et al., 2001:2006). 
Studies have demonstrated that both receptor subtypes are capable of mediating estrogen 
neuroprotection (Zhao et al., 2004; Miller et al., 2005; Cordey and Pike, 2005; Liu et al., 
2005; Zhao and Brinton, 2007). The differential expression and localization of ER 
isoforms underlies their distinct roles in various biological functions. Distinguishing the 
role of each receptor isoform in estrogen neuroprotection will assist the development of 
ER-subtype selective ligands to target the beneficial actions of estrogen and avoid 
unwanted side effects. In these experiments, we proposed that estrogen attenuation of 
Tat-induced apoptotic signaling was receptor mediated, furthermore, these estrogen 
effects are specific to ER-subtype. 
3.2. Experimental Design 
 We investigated if estrogen effects on expression of apoptotic markers in Tat exposed 
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cortical cultures were estrogen receptor- mediated.  We determined if estrogen effects on 
apoptotic markers were maintained in the presence of non-specific ER antagonist 
ICI182,780 (100nM), which blocks both ERα and ERβ.   Additionally, ICI-sensitive 
apoptotic proteins were further evaluated to determine whether estrogen effects are 
specific to ER subtype.  Specific antagonists of ERα (1000 nM, MPP dihydrochloride)  
and ERβ (1000 nM, PHTPP) were administered 1h before estrogen treatment. 
3.3. Materials and Methods 
3.3.1 .Immunocytochemistry 
For immunocytochemistry experiments,  Tat-treated cultures and Estradiol+Tat-
treated controls were fixed in acetic alcohol (95% ethanol, 5% acetic acid) for 10 min and 
washed three times (5 min/wash) with Dulbecco phosphate-buffered saline (D-PBS): 
Na2HPO4 (1150 mg/L), KH2PO4 (200 mg/L), NaCl (8000 mg/L), KCl (200 mg/L) at pH 
7.4. Following fixation, cultures were blocked with 10% normal horse serum (NHS) in 
PBS and used for the analysis. 
3.3.2. Anti-ERα and anti-ERβ immunofluorescence 
Rabbit polyclonal anti-ERα (Santa Cruz) and anti-ERβ (Affinity Biosciences) 
antibodies were used to detect expression of estrogen receptors in nontreated cortical 
cultures. Primary antibodies were diluted 1:500 in 1% NHS/PBS.  Cell cultures were 
incubated with primary antibodies overnight at 4°C. Each set of experiments included cell 
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culture dishes which were left without primary antibody.  These cell cultures served as 
controls for non-specific binding of secondary antibodies.  After incubation with primary 
antibodies was complete, plates were washed three times (5 min/wash) with PBS. For the 
immunofluorescent detection of Tat immunoreactivity goat anti-rabbit IgG conjugated 
with Alexa 594 dye (Molecular Probes) diluted 1:500 in 1% NHS/PBS was used. Plates 
were incubated with secondary antibodies for 1h at room temperature and then washed 3 
times with PBS. Cells were counterstained with DNA binding fluorescent Hoecsht dye.  
3.3.3. Anti-Tat immunofluorescence 
Rabbit polyclonal Tat antibody (Diatheva, Italy) was used to determine Tat 1-86 
immunoreactivity.  Primary antibodies were diluted 1:500 in 1% NHS/PBS.  Cell cultures 
were incubated with primary antibodies overnight at 4°C. Each set of experiments 
included cell culture dishes which were left without primary antibody.  These cell 
cultures served as controls for non-specific binding of secondary antibodies.  After 
incubation with primary antibodies was complete, plates were washed three times 
(5min/wash) with PBS. For the immunofluorescent detection of Tat immunoreactivity 
goat anti-rabbit IgG conjugated with Alexa 594 dye (Molecular Probes) diluted 1:500 in 
1% NHS/PBS was used. Plates were incubated with secondary antibodies for 1h at room 
temperature and then washed 3 times with PBS. 
Microscopic images of Tat immunoreactivity in primary cell cultures were captured using 
the computer-controlled inverted fluorescent microscope (Nikon Eclipse TE2000-E) 
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under 20x magnification and analyzed using NIS-Elements BR 2.30 imaging software 
package (Nikon). Images of specific Tat immunofluorescence were merged with the 
subsequent differential interference contrast (DIC) images.   
3.3.4. Detection of Apoptotic proteins (ELISA) 
Expression of apoptotic signaling proteins in cell lysates was determined by 
ELISA. Cell lysates were prepared from cultures grown in 24-well plates. Cultures were 
treated with ICI182,780 (100 nM), MPP (1000 nM), or PHTPP (1000 nM) 1h prior to 
addition of 17β-estradiol (10 nM). After 24h estradiol pretreatment, cell cultures were 
exposed to 50nM Tat 1-86 for 4, 16, or 24 hours before harvesting.  At the time of 
harvesting, medium was removed and cells were washed three times with Dulbecco 
phosphate-buffered saline, D-PBS, (8 mM Na2HPO4, 1.5 mM KH2PO4, 0.137 M NaCl 
and 2.7 mM KCL at pH 7.4) and lysed with CellLytic 
TM
- M mammalian cell lysis buffer 
(Sigma Chemicals) containing protease inhibitors (protease inhibitors cocktail, Sigma 
Chemicals). All samples in a group (6 sister culture wells) were pooled together and 
protein concentration was determined by BCA method (Pierce).  Each well of Costar 96-
well ELISA plates (Corning Inc, PA) was coated overnight at 4 °C using 100 μl of 
20 mM carbonate coating buffer, pH 9.6. Cortical cell lysate samples were diluted 1:10 
with D-PBS and 2 ug of each sample were added to the plate wells. After overnight 
incubation at 4 °C, plates were rinsed 5 times with PBST (0.05% Tween 20 in PBS, 
pH = 7.4) and blocked with 1% BSA in PBS for 2 h at room temperature. After blocking, 
plates were washed again as described above and primary anti-Bax, anti-Bcl-2, anti- 
 
 
61 
active Caspase 9 and anti- active Caspase 3 antibodies (all primary antibodies, Abcam, 
Cambridge, MA) diluted 1:5000 or 1:7500 (caspase 3) in 0.1% BSA-PBST were added to 
each well except for blanks and no-primary antibody control wells. Plates were kept 
overnight at 4 °C. When the incubation with primary antibodies was completed, plates 
were again washed 5 times with PBST and secondary antibodies (goat anti-rabbit alkaline 
phosphatase conjugated, Sigma) diluted 1: 2000 in 0.1% BSA-PBST were added to each 
well except for blank and no-secondary antibody control wells. After 2 h of incubation, 
secondary antibody solution was removed, plates were washed 5 times with PBST and 
100 μl of BluePhos phosphatase substrate mixture (KPL Research, Gaithersburg, MD) 
was added to the plate wells. After 30 min of incubation, the absorbance at 650 nm was 
determined using a Bio-Tek Synergy HT microplate reader. Multiple readings were taken 
within a 1-h time period.  
3.4. Statistical Analysis 
Statistical comparisons were made using one way ANOVA and Tukey’s multiple 
comparison tests to determine specific treatment effects. Significant differences were set 
at p<0.05.  Data represent percent of control values.  
3.5. Results 
3.5.1. Estrogen receptor expression in cortical cell culture 
Estrogen receptor expression was determined in non-treated primary cortical 
 
 
62 
cultures.  Neurons positively stained for anti-ERβ and anti-ERα antibodies were present 
in cortical cultures (Figure 3.1). Anti-ERα immunoreactivity was mainly localized in 
nuclei, while ERβ immunofluorescence was also observed in nuclei, however, staining 
was also detected in cytoplasm with the nuclei unstained.   
3.5.2. Estrogen effects on Tat interaction with neuronal membranes 
Because neurons are not directly infected with HIV, Tat-induced neuronal 
apoptosis may be dependent upon Tat binding/interaction with neuronal membranes. The 
presence of estrogen membrane receptors are generally acknowledged and are thought to 
mediate estrogen rapid cellular effects. We determined if estrogen attenuation of Tat-
induced apoptosis was mediated by preventing or interfering with mechanisms of Tat 
binding and uptake by neurons in culture. Immunostaining of cell cultures exposed for 2h 
to 50 nM Tat 1-86 alone or in the presence of 10 nM of 17β-estradiol with anti-Tat 
antibodies showed the presence of Tat in nuclei, but in some neurons anti-Tat 
immunofluorescence was localized in somata, leaving nuclei unstained (Figure 3.2).  Tat 
immunoreactivity was assessed in estradiol pretreated and Tat-alone treated cultures. 
Results demonstrate no differences in anti-Tat immunoreactivity with estradiol 
pretreatment, as significant anti-Tat immunofluorescence was still detected and was 
comparable to that observed in Tat-alone treated cultures. 
3.3.3. Estrogen receptors mediate 17β- estradiol effects against Tat-induced Bax not Bcl-
2 
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To determine potential mechanisms of estrogenic action, we investigated the 
effects of ICI 182780, a specific ER antagonist, on 17β-estradiol- inhibition of apoptotic 
protein expression in Tat treated cell cultures.  Cell cultures were incubated for 1hr with 
ICI 182,780 (100nM) before the addition of 17β-estradiol and then exposed to 50nM Tat 
1-86 for 4, and 16 h. The addition of ER antagonist was able to block estrogen protective 
effects on Tat-induced Bax protein expression (4 h Tat exposure), as Bax levels were 
similar to that of cultures treated with Tat alone (134±6%, p<0.05, compared to Tat+E 
treated cultures) (Figure 3.3A).  Results indicate that ICI 182,780 was not able to block 
estrogen actions on Bcl-2 expression with Tat exposure  (16 h) (Figure 3.3B). There was 
no significant difference in Bcl-2 levels in 17β-estradiol treated and ICI 182,780 treated 
cortical lysates.  
3.3.4. Estrogen receptors mediate 17β-estradiol effects on caspase 3 activity in Tat-
exposed cortical cultures 
We also evaluated if estrogen receptors play a role in regulation of active caspase 
expression.   ICI treatment displayed no effect on active caspase 9 expression at 4h of Tat 
exposure, as estrogen effects on caspase 9 were maintained, suggesting the estrogen 
actions on caspase 9 are not receptor-mediated (Figure 2.4A). However, estrogen effects 
on caspase 3 expression were significantly attenuated by ICI treatment. At each time 
point evaluated, estrogen actions on Tat-induced caspase 3 expression were ICI-sensitive, 
as caspase levels in ICI treated cultures were not significantly different from those 
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present in cultures treated with Tat alone (Figure 2.4B).  
3.3.5. ER subtypes differentially mediate estrogen effects on caspase 3 activity and Bax 
expression following Tat exposure  
We then used ER subtype-selective antagonists to further define whether ER 
effects were mediated by either ERα and/or ERβ. ERα and ERβ specific antagonists, 
MPP dihydrochloride and PHTPP respectively, were added to cultures prior to17 β-
estradiol treatment.  Furthermore, results indicated that the addition of either MPP or 
PHTPP was unable to attenuate 17 β-estradiol effects on caspase expression, suggesting 
that 17 β-estradiol actions on Tat-induced caspase expression are mediated by both ER 
subtypes (Figure 2.5A).  
In regard to Bax, the addition of MPP only partially attenuated estrogen effects on 
Bax expression, while the addition of PHTPP markedly abrogated estrogen 
downregulation of Bax (Figure 2.5B).  
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Figure 3.1. Estrogen receptor expression in primary cortical cultures. Microscopic 
images of ERα (A) and ERβ (B) expression (red fluorescence) in primary cortical 
cultures. Left panel displays overlap of anti-ER fluorescence and Hoechst nulear stain. 
Right panels show the individual images of ER expression and nuclear staining. White 
boxes demonstrate classic nuclear localization of ERα and ERβ. In green circles, ERβ 
immunoreactivity was also detected in cytoplasm of some neurons. 
B. 
A
.
. 
 
 
66 
 
 
Figure 3.2. Image of Tat immunoreactivity in rat fetal cortical cell cultures. Tat-
immunopositive cells were detected in cortical cultures pretreated with 10nM 17β-
estradiol and/or exposed to 50nM Tat 1-86 for 2h. No differences in Tat 
immunoreactivity (Red arrows) was detected between estrogen pretreated (B) and Tat-
alone treated cultures (A). Note not all cells express Tat immunoreactivity (Blue arrows). 
 
 
 
 
 
 
 
 
 
A. B. 
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3.3. Tat-induced Bax expression sensitive to estrogen receptor -mediated estrogenic 
actions. A. Estrogen effects on Bax after 4h of  Tat exposure were reversed by ICI 
182,780, suggesting that estrogenic actions on Bax are mediated by ER signaling. B. 
Estrogen effects on Bcl-2 expression (16h Tat exposure) were not attenuated by the 
addition of ER antagonist. Experiments performed in triplicate, *p<0.05 as compared to 
Tat-treated cultures, **p<0.05 compared to Tat treated cultures, #p<0.05 as compared to 
Tat+E treated cultures.  
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Figure3.4. Estrogen receptor mediates estrogen effects on Tat-induced Caspase 3 
not Caspase 9 active expression. Estrogen receptor antagonist, ICI 182,780, was added 
to cultures 1h before treatment with 17β-estradiol. A. Estrogen effects on caspase 9 
expression (4 h of Tat exposure) were maintained in presence of ER antagonist. B. 
Estrogen effects on Tat-induced expression of caspase 3 were reversed by ICI 182,780, 
suggesting that estrogenic actions on caspase 3 are ER mediated. Experiments performed 
in triplicate, *p<0.05 as compared to controls, **p<0.05 as compared to Tat-treated 
cultures, #p<0.05 as compared to Tat+E treated cultures. 
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Figure 3.5. Estrogen receptor subtype specific effects against caspase activity and 
Bax expression. (A.) Estrogen effects against Tat-induced caspase 3 activity were 
maintained in presence of specific antagonists for ERα (MPP, 100nM) and ERβ (PHTPP, 
100nM).  (B.) ER subtype specific antagonists reveal that ERβ mediated signaling 
preferential for estrogen effects on Bax. Experiments performed in triplicate, *p<0.05 as 
compared to controls, **p<0.05 as compared to Tat treated cultures, #p<0.05 as 
compared to Tat+E treated cultures.  
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3.6. Discussion 
Recently, much attention has been given to the neuroprotective properties of 
estrogens for chronic neurodegenerative diseases.  In vivo and in vitro studies show that 
estrogens can protect against a number of neurotoxic compounds (Green and Simpkins, 
2000; Turchan et al., 2001). The mechanisms by which estrogen protects cells can 
include receptor-mediated and non-receptor-mediated effects. Estrogen receptors are 
widely expressed in the brain with some regional differences.    We demonstrated the 
presence of estrogen receptors in the primary cortical cultures by immunocytochemistry. 
We found that estrogen receptors are localized in neurons and display nuclear and 
cytoplasmic distribution.  
Images of Tat immunoreactivity in cultured rat fetal cortical neurons treated with 
50nM Tat 1-86 shows that when levels of cell bound Tat was maximal, the culture 
contained populations of Tat positive and Tat negative neurons. This indicates rat fetal 
neurons in cell culture may differ in their ability to interact with extracellular Tat.  
Moreover, this pattern of Tat immunoreactivity did not change in the presence of 
estrogen. Such observations seem to indicate that membrane actions of estrogen are not 
involved in its attenuation of Tat-induced cell death, as it does not augment the direct 
interaction of Tat with neurons.  
The direct interaction of Tat with neuronal cell membranes involves binding and 
uptake into the cell and translocation of Tat into the nuclei.  The nuclear localization and 
Tat transcriptional effects may contribute to neuronal apoptosis. The nucleus represents 
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an ideal site for estrogen protection. Although not assessed in these experiments, the 
nuclear colocalization of Tat and estrogen receptors supports the notion of direct estrogen 
effects against Tat induced transcriptional events. And suggests a more classical action of 
estrogen via its nuclear receptors 
It is widely accepted that the biological actions of estrogen are mediated by two 
different receptor subtypes, ERα and ERβ. We next determined that 17β-estradiol 
protected against the neurotoxic insult of HIV-1 Tat via an ER-mediated mechanism.  
Results demonstrate that the addition of a nonspecific ER antagonist ICI 182,780, which 
blocks both ERα and ERβ, attenuated the estrogen down-regulation of Bax and caspase 3 
with Tat exposure.  Using subtype-specific antagonists we sought to further determine if 
these estrogen effects were selectively mediated by either ERα and/or ERβ. The ERα-
specific antagonist MPP and ERβ-specific antagonist PHTPP did not attenuate the 
estrogen effects on caspase 3 expression. Our results indicated that estrogen receptor-
mediated effects on Tat-induced caspase 3 expression are not selective to a specific ER 
subtype. However, estrogen effects on Bax are preferential for ERβ mediated signaling, 
although ERα did contribute to these effects as well.  
Estrogen actions on caspase 9 expression and Bcl-2 levels were maintained in 
presence of antagonists, implying these estrogen actions are not receptor-dependent.  
These results suggest that ERs may be involved in select aspects of apoptotic signaling.  
Indeed, a previous report has shown that HIV-1 Tat toxic effects on mitochondria and 
neuronal cell survival may be independently regulated (Turchan et al., 2001). It seems 
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that estrogens are protective against both mitochondrial dysfunction and cell death by 
receptor and non-receptor mediated mechanisms. More evidence indicates that in 
addition to the genomic ER-mediated effects, many effects of estradiol may involve cross 
talk with other signal transduction pathways (Mhyre & Dorsa, 2006). Estrogen may act 
via an indirect, non-genomic response involving activation/phosphorylation of Akt which 
can mediate the anti-apoptotic signaling pathway and involves regulation of the 
antiapoptotic protein Bcl-2 (Honda et al.,2000; Singh, 2001).   
Recent reports are suggesting the mitochondria as a promising target for estrogen-
mediated protection (Arnold and Beyer, 2009; Klinge, 2008; Simpkins and Dykens, 
2008). There is evidence that estrogen receptors and estrogen-binding proteins are located 
in the mitochondrial matrix or mitochondrial membranes.  Activation of the nuclear ERs 
may directly regulate mitochondria by controlling the transcriptional activity of genes 
coding for mitochondrial associated proteins (Arnold and Beyer, 2009). The substantial 
effect of estrogen on Bax expression may relate to the mitochondrial localization of ERs, 
particularly as a recent study reported that ERβ colocalized with a mitochondrial marker 
in rat primary cortical and hippocampal neurons (Yang et al., 2004).  
Exposure to HIV-1 viral proteins initiates a significant toxic cascade that likely 
involves activation of multiple cell death pathways. It is clear, that estrogen was able to 
attenuate Tat-induced apoptotic signaling and prolonged cell viability.  With the 
induction of many apoptotic pathways and different factors/mediators of execution, it is 
difficult to delineate a point of convergence of the various pathways, which would be 
ideal as a target to interrupt the apoptotic process and support cell survival. However, the 
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ER-β appears to be a primary point for pharmacological targeting.  
  Although it is popular theory that these apoptotic processes occur in a sequential 
pattern, this may not be the case in all cell death mechanisms.  Disruption of 
mitochondrial function can kill cells without caspase activation (Hirsch et al., 1997). In 
contrast, in several cases, caspase inhibition delays and sometimes prevents 
mitochondrial dysfunction (Hirsch et al., 1997;  Susin et al., 1997; Bossy-Wetzel et al., 
1998), caspases can cause mitochondrial dysfunction in vitro, and mitochondrial events 
can cause caspase activation (Zhou et al., 1997;Li et al., 1997; Kluck et al., 1997; Yang et 
al., 1997). It is plausible that caspase activation and disruption of mitochondrial function 
occur in a circular feedback loop. In such a scenario, mitochondrial dysfunction would 
release caspase activators at the same time as caspases might act on mitochondrial 
membranes. Caspase inhibition might retard but not prevent cell death because it slows 
down a caspase-dependent self-amplification loop resulting in acceelerated mitochondria 
dysfunction.  
Both mitochondrial membrane function and caspases are crucially involved in cell 
death and seem to represent key checkpoints in the regulation of cell death. The circular 
model of apoptotic events reflects our observations of simultaneous upregulation of 
proapoptotic factors Bax, indicating mitochondria membrane permeability, disruption of 
mitochondrial membrane potential, and caspase activation early after Tat exposure. More 
interesting is the specific estrogen receptor mediated effects on Bax expression and 
caspase 3 activity, further indicating the important role of membrane permeability and 
 
 
74 
execution phase of apoptotic cell death. Caspase-3 is considered to be the most important 
of the executioner caspases and is activated by any of the initiator caspases.   
Additionally, these events might constitute a point of integration of multiple apoptotic 
pathways as several pro-apoptotic second messengers, including Ca2+ ions, ROS, 
ceramides, caspases and Bax facilitate their function. Multiple apoptotic pathways end at 
the point of the execution phase, considered the final pathway of apoptosis. 
In summary, the present study suggests the neuroprotective actions of estrogen 
against HIV-1 Tat-mediated toxic insults involve regulating ER-responsive apoptotic 
factors.  Our results indicated that HIV-1 Tat-mediated cell death induces key regulatory 
factors of the mitochondria-linked apoptotic pathway.  Estrogen treatment was effective 
in delaying cell death that involved attenuating Tat- induced caspase activity and pro-
apoptotic protein expression. The protective estrogenic effect was mediated by an ER-
sensitive mechanism specific to Bax and caspase 3. Furthermore, the present study 
indicated that both ERα and ERβ may contribute to the beneficial actions of estrogen, 
with some selective effects of ERβ. 
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CHAPTER 4 
Experiment 3. To determine if phytoestrogens are equally effective as endogenous 
estrogen against Tat-induced apoptotic signaling. 
4.1. Introduction 
Since estrogen acts as a neurotrophic and neuroprotective factor, women in a 
hypoestrogenic state are more vulnerable to neurodegenerative conditions.  However, in 
spite of the beneficial effects of estrogen, hormone therapy is met with resistance due to 
its association with reproductive and breast cancers.  Therefore, there is great need to 
establish the mechanism(s) underlying estradiol mediated protection.  Many studies 
suggest that estradiol-mediated protection may involve attenuation delayed cell death 
(Dubal et al., 2006). Estrogen can protect against neuronal apoptosis by regulating 
caspase activities and  expression of anti-apoptotic proteins and maintaining 
mitochondrial functioning (Wang et al., 2001; Sawada et al., 2000). There is growing 
interest in the functions of phytoestrogens, such as soy isoflavones (genistein and 
daidzein), including whether they have beneficial effects on neurodegenerative disease. 
These soy isoflavones may mimic the actions and functions of estrogen in the brain, as 
they bind to the estrogen receptor and affect estrogen mediated processes. Several studies 
have shown that soy isoflavones have neuroprotective effects against various neurotoxic 
 
 
76 
insults that involved preventing oxidative stress, regulating anti-apoptotic proteins, and 
reducing caspase activation. In this experiment we propose that phytoestrogens mimic 
estrogenic actions against Tat-induced apoptotic signaling via a similar ER mediated 
mechanism.  
4.2. Experimental Design 
Enzyme-linked immunosorbent assay (ELISA) was used to quantify levels of apoptotic 
signaling proteins Bax, Bcl-2, active caspase 9 and active caspase 3 in cortical lysates 
incubated with phytoestrogens, genistein (GEN), and daidzein (DAI) prior to Tat 
exposure. Cells were incubated with 17β-estradiol (10 nM), GEN, or DAI (1000 nM) 24 
hours prior to Tat exposure.  Tat treated cell cultures were exposed to 50 nM Tat 1-86 for 
4, 16, or 24 hours before harvesting. ELISA experiments were performed as described in 
Experiment 1. We determined if phytoestrogens are as effective as endogenous estrogen, 
17β-estradiol, in attenuating Tat-induced cell death signaling. 
4.3. Materials and Methods 
4.3.1. Detection of Apoptotic proteins (ELISA) 
Expression of apoptotic signaling proteins in cell lysates was determined by 
ELISA. Cell lysates were prepared from cultures grown in 24-well plates. Tat treated cell 
cultures were exposed to 50 nM Tat 1-86 for 4, 16, or 24 hours before harvesting.  At the 
time of harvesting, medium was removed and cells were washed three times with 
Dulbecco phosphate-buffered saline, D-PBS, (8 mM Na2HPO4, 1.5 mM KH2PO4, 0.137 
 
 
77 
M NaCl and 2.7 mM KCL at pH 7.4) and lysed with CellLytic 
TM
- M mammalian cell 
lysis buffer (Sigma Chemicals) containing protease inhibitors (protease inhibitors 
cocktail, Sigma Chemicals). All samples in a group (6 sister culture wells) were pooled 
together and protein concentration was determined by BCA method (Pierce, Rockford, 
Ill.).  Each well of Costar 96-well ELISA plates (Corning Inc, PA) was coated overnight 
at 4 °C using 100 μl of 20 mM carbonate coating buffer, pH 9.6. Cortical cell lysate 
samples were diluted 1:10 with D-PBS and 20ug of each sample were added to the plate 
wells. After overnight incubation at 4 °C, plates were rinsed 5 times with PBST (0.05% 
Tween 20 in PBS, pH = 7.4) and blocked with 1% BSA in PBS for 2 h at room 
temperature. After blocking, plates were washed again, as described above, and primary 
anti-Bax, anti-Bcl-2, anti- active Caspase 9 and anti- active Caspase 3 antibodies (all 
primary antibodies, Abcam, Cambridge, MA) diluted 1:5000 or 1:7500 (caspase 3) in 
0.1% BSA-PBST were added to each well except for blanks and no-primary antibody 
control wells. Plates were kept overnight at 4 °C. When the incubation with primary 
antibodies was completed, plates were again washed 5 times with PBST and secondary 
antibodies (goat anti-rabbit alkaline phosphatase conjugated, Sigma) diluted 1: 2000 in 
0.1% BSA-PBST were added to each well except for blank and no-secondary antibody 
control wells. After 2 h of incubation, secondary antibody solution was removed, plates 
were washed 5 times with PBST and 100 μl of BluePhos phosphatase substrate mixture 
(KPL Research, Gaithersburg, MD) was added to the plate wells. After 30 min of 
incubation, the absorbance at 650 nm was determined using a Bio-Tek Synergy HT 
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microplate reader. Multiple readings were taken within a 1-h time period.  
4.4. Statistical Analysis 
Statistical comparisons were made using one-way ANOVA and Tukey’s multiple 
comparison tests were used to determine specific treatment effects. Significant 
differences were set at p<0.05.  Data represent percent of control values.  
4.5. Results 
4.5.1. Effects of genistein and daidzein on Tat-induced caspase activation in primary 
fetal rat cortical cell cultures 
We compared the protective effect of 17 β-estradiol and phytoestrogens genistein 
(GEN) and daidzein (DAI) in cortical neuronal cultures exposed to 50 nM Tat 1-86. 
Previous experiments demonstrated that Tat exposure caused a significant increase in 
caspase 9 activation. Moreover, the addition of 17 β-estradiol was able to significantly 
attenuate this induction of caspase 9 activity. In the present experiments, we evaluated 
the protective efficacy of GEN and DAI against Tat-induced upregulation of caspase 9 
activity.  Figure 4.1A shows significant caspase 9 activation following only 4 hr of Tat 
exposure (p<0.05). Preincubation with 10nM estradiol or 1000nM of phytoestrogens 
genistein (GEN) or daidzein (DAI) prevented the increase in Tat-induced caspase 3 
activation.  Similar to estradiol, in the presence of genistein or daidzein, the expression of 
active caspase 9 was diminished by ~20% vs. Tat-alone treated cultures (p<0.05). 
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Moreover, analysis revealed that caspase 9 activity was not statistically different between 
the 17β-estradiol, GEN and DAI pretreated cultures.  
In regard to effector caspase 3 activity, a similar effect was observed with 
phytoestrogen pretreatment prior to Tat exposure.  Results demonstrate a significant 
increase in caspase 3 activation in cortical cultures following 4h exposure to Tat 
(p<0.05).  The addition of 17β-E2 was able to attenuate the increase in caspase 3 
observed with Tat exposure.  The current experiments show that the addition of GEN or 
DAI prior to incubation with 50nM Tat significantly attenuated the upregulation of active 
caspase 3 expression (p<0.05, Figure 4.1B).  The level of activation of caspase 3 in GEN 
and DAI pretreatment groups was not significantly different from that of vehicle-treated 
controls, furthermore these levels were very similar to that of the endogenous estradiol.  
These results indicate that isoflavones GEN and DAI downregulate Tat-induced caspase 
activation to a level comparable to  that of 17β-E2, suggesting that isoflavones and 
estradiol may share a common neuroprotective mechanism.  
4.5.2.  Effects of genistein and daidzein on pro- and anti-apoptotic proteins Bax and Bcl-
2 upregulation in Tat-exposed primary cortical cell cultures 
 Bcl-2 is an anti-apoptotic protein, thought to regulate the permeability of the  
mitochondrial membrane, and prevent the release of apoptotic factors that initiate the  
caspase cascade leading to cell death.  Our prior experiments have shown that incubation 
with Tat (16 h) caused a significant upregulation of Bcl-2 expression in cortical cell 
cultures. With the addition of 17β-E2, we observed an attenuation of Tat-induced Bcl-2 
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expression.    Results of the current experiment indicate that similar to estradiol, GEN 
and DAI significantly attenuated the increase of Bcl-2 expression following Tat exposure 
(p<0.05). Bcl-2 levels in the estradiol and isoflavone treated cultures were not 
significantly different from that of vehicle-treated controls, nor was there any statistical 
difference between the treatment groups.  
 We also evaluated the efficacy of isoflavones against Tat-induced Bax expression.  
Bax is a pro-apoptotic protein, that opposes the actions of Bcl-2, that also effects 
mitochondrial membrane permeability. Over-expression of Bax increases the 
permeability of the mitochondrial membrane, allowing the release of apoptotic factors 
which activate the caspase cascade.  Results demonstrate that 24h pretreatment with GEN 
or DAI was able to significantly block the induction of Bax expression following 
exposure to Tat (p<0.05).  In addition, this effect on  Bax expression was similar across 
the 17β-estradiol, GEN and DAI treatment groups.  
4.5.3. Estrogen Receptor-Mediated effects of genistein and daidzein against Tat-induced 
caspase 3 activation and Bax expression in primary cortical neuronal cultures 
As phytoestrogens have been shown to affect estrogenic processes, it is thought 
that they may act via a similar mechanism as estradiol.  Many of estrogens effects are 
mediated by estrogen receptors, ERα and ERβ.  The expression of both receptor subtypes 
has been determined in cortical regions of the human and rat brain, moreover the 
expression of estrogen receptors has been observed in vitro in cortical cell cultures.  In 
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the present experiments, we sought to determine if the protective actions of 
phytoestrogens against Tat-induced apoptotic process were mediated by estrogen 
receptors. The ER antagonist, ICI182,780  (ICI,100 nM) was added to cultures 1h prior to 
incubation with GEN and DAI.  Prior experiments have shown that endogenous 17β-
estradiol effects against caspase 3 were receptor mediated, as the addition of ICI prior to 
estradiol returned caspase 3 activation levels to that of Tat-alone treated cultures. Results 
of the current experiments indicate that ICI prevented the downregulation of caspase 3 
activation observed with GEN pretreatment (Figure 4.3A). Caspase 3 activity in ICI 
treated cultures was significantly higher than GEN+Tat treated cortical cultures (177±10 
vs. 107±8, p<0.05) and caspase 3 activity was returned to levels similar to that of Tat-
alone treated cultures. We also observed that DAI effects on caspase 3 were mediated via 
an ICI-sensitive mechanism. There was a 40% increase in active caspase 3 expression 
with the addition of ICI compared to DAI+Tat treated cultures (p<0.05). Moreover, 
caspase 3 activity did not differ statistically from that of Tat-alone treated cultures.   
We then evaluated if GEN and DAI effects were specifically selective to ER 
subtype. The ER-subtype specific antagonists MPP dihydrochloride (ERα) and PHTPP 
(ERβ) (1000 nM) were added to cortical cultures prior to incubation with GEN or DAI 
and subsequent exposure to 50 nM Tat.  The addition of ERα or ERβ antagonist did not 
attenuate the protective effects of GEN or DAI against Tat-induced caspase 3 activation 
(Figure 4.4A).  The protective effect of GEN and DAI was maintained in presence of 
ERα and ERβ specific inhibitors. The ER subtype selective antagonists on partially 
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attenuated the down regulation of caspase 3 activation in cultures treated with isoflavones 
GEN and DAI.  Even in the presence of the antagonist a similar effect on caspase 
activation is seen in GEN and DAI pretreated cultures. Interestingly, no difference in 
caspase activity is observed between the GEN and DAI treated cultures.  Moreover, this 
profile of caspase activation is quite similar to that observed in 17β-estradiol treated 
cultures with the addition of ER subtype antagonists. 
 We have also previously shown that estrogen downregulation of Tat-induced Bax 
expression was mediated by estrogen receptors. To evaluate if GEN and DAI effects on 
Bax expression are ER-mediated, cultures were incubated with the general ER antagonist 
ICI 182,780 (ICI).  ICI exposure blocked GEN and DAI effects against Tat-induced Bax 
expression. A significant 25% increase in Bax expression was seen with ICI treatment 
prior to incubation with GEN or DAI (p<0.05) (Figure 4.3B).  We then sought to 
determine if the protective effects of GEN and DAI against Tat-induced expression of 
Bax was mediated by a specific ER-subtype. The ER-subtype specific antagonists MPP 
dihydrochloride (ERα) and PHTPP (ERβ) (1000 nM) were added to cortical cultures 
prior to incubation with GEN or DAI and subsequently exposed to 50 nM Tat.  The 
addition of ERα antagonist MPP attenuated GEN effects on Bax expression, however, 
GEN downregulation of Bax was markedly abrogated in the presence of ERβ antagonist 
PHTPP (Figure 4.4B).  A similar profile of Bax expression was observed in DAI+Tat 
treated cultures in the presence of the ER subtype antagonists. The addition of MPP and 
PHTPP significantly blocked DAI downregulation of Bax expression; however this 
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suppression of DAI effect was slightly higher in the presence of the ERα antagonist MPP. 
Although, results suggest that both ER subtypes mediate DAI effects on Bax expression.  
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Figure 4.1. Phytoestrogens attenuate Tat-induced caspase activation in primary 
cortical cultures.  Cortical cultures were treated with 1μM GEN or DAI 24h prior to Tat 
exposure. Expression of apoptotic proteins A. Caspase 9 (4h of Tat exposure) and B. 
caspase 3 activity (4h Tat exposure) was assessed by ELISA experiments. Results are 
presented as % of control value, with experiments performed in triplicate, * p< 0.05 as 
compared to control cultures, **p< 0.05 as compared to Tat-treated cultures. 
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Figure 4.2. Phytoestrogens attenuate Tat-induced expression of Bcl-2 and Bax 
protein levels.  Cortical cultures were treated with 1μM GEN or DAI 24h prior to Tat 
exposure. Expression of apoptotic proteins A. Bcl-2 (16h of Tat exposure) and B. Bax 
(4h Tat exposure) were assessed by ELISA experiments. Results are presented as % of 
control value, with experiments performed in triplicate, * p< 0.05 as compared to control 
cultures, **p< 0.05 as compared to Tat-treated cultures. 
Bcl-2 
Tat EST+T GEN+T DAI+T
Im
m
u
n
o
re
a
c
ti
v
it
y
, 
%
 o
f 
c
o
n
tr
o
l
0
20
40
60
80
100
120
140
160
** ** **
*
 
Bax
Tat EST+T GEN+T DAI+T
Im
m
u
n
o
re
a
ct
iv
ity
, 
%
 o
f 
co
n
tr
o
l
0
20
40
60
80
100
120
140
160
180
** ** **
*
 
 
 
86 
A. 
 
 
 
 
 
 
B. 
 
 
 
 
 
 
 
 
 
Figure 4.3. ERs mediate phytoestrogen effect on Caspase 3 and Bax expression in 
Tat exposed cortical cultures. A. GEN or DAI effects on caspase 3 expression were 
blocked in the presence of ER antagonist, ICI 182,780. B. GEN or DAI effects on Tat-
induced expression of Bax were reversed by ICI , suggesting that estrogenic actions on 
caspase 3 and Bax are ER mediated. * p< 0.05 as compared to control cultures, **p<0.05  
as compared to Tat-treated cultures.#p<0.05 vs. GEN/DAI+T treated cultures. 
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Figure 4.4. ER subtype specific effects against caspase activity and Bax expression. 
(A)GEN and DAI effects against Tat-induced caspase 3 activity were maintained in 
presence of specific antagonists for ERα (MPP) and ERβ (PHTPP). (B)ER subtype 
antagonists reveal that ERβ signaling preferential for GEN effects on Bax. DAI effects on 
Bax were blocked in presence of both ER subtype antagonists. Experiments performed in 
triplicate, * p< 0.05 as compared to control cultures, **p< 0.05 as compared to Tat-
treated cultures. #p<0.05 as compared to GEN/DAI +Tat treated cultures. 
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4.6. Discussion 
In the present study, we evaluated the neuroprotective efficacy of phytoestrogens 
genistein (GEN) and daidzein (DAI) against HIV-1 Tat-triggered mitochondrial-mediated 
apoptosis pathway. The goal of the present study was to evaluate the protective effect of 
phytoestrogens on Tat-induced activation of the mitochondrial- mediated apoptotic 
pathway. The neurotoxic potential of the HIV-1 Tat protein has been well documented in 
various cell culture models (Bonavia et al., 2001; Aksenov et al., 2006:2009; Adams et 
al., 2010).  Recent studies have indicated that an apoptotic process is involved in Tat –
induced cell death.  Mitochondria are known to be involved in apoptosis by releasing 
apoptogenic substances into the cytoplasm to activate the caspase cascade, including key 
apoptotic initiatior caspase 9 and executor caspase 3. We found that exposure to 50nM 
Tat 1-86 caused significant increases in caspase 9 and caspase 3 activities in primary 
cortical culture.  As observed previously with endogenous 17β-estradiol, phytoestrogens 
genistein and daidzein prevented the upregulation of caspase activity in Tat-exposed 
cultures.  In addition, upstream of caspase activation, we show that Tat exposure 
significantly increased expression of pro- and anti-apoptotic proteins Bax and Bcl-2, 
which regulate mitochondrial membrane permeability and thus, the release of 
apoptogenic substances. Our results indicate that treatment with phytoestrogens genistein 
and daidzein also markedly reduced the expression of Bax and Bcl-2 in Tat-exposed 
cortical cultures.  These results indicate that the beneficial/protective effect of genistein 
and daidzein is via inhibition of the mitochondria-mediated apoptotic pathway.   
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Both soy isoflavones genistein and daidzein exhibited protective effects similar to 
that achieved by 17β-estradiol. Since phytoestrogens are able to bind ERs, such actions 
may be produced through activation of the ER. In the present study, we found that the 
addition of the non-specific ER antagonist ICI 182,780, which blocks both ERα and ERβ, 
attenuated genistein and daidzein downregulation of caspase 3 and Bax with Tat 
exposure, suggesting that these effects were mediated by ERs.  The addition of ICI had a 
more robust effect against genistein actions on caspase 3 activity, as levels were nearly 
the same as that of Tat-alone treated cultures.  ICI only partly attenuated the daidzein 
effects on caspase activation. Furthermore, phytoestrogen effects on Bax expression were 
also shown to be ER-dependent, as the addition of ICI significantly attenuated genistein 
and daidzein downregulation of Tat-induced Bax expression.  These results suggest that 
genistein and daidzein act as estrogen receptor agonist in primary cortical neurons and 
that they may have neuroprotective effects in vivo.  
Caspase 3 is a member of the caspase family of proteins that is activated in 
response to apoptotic signals coming either from the mitochondria via caspase 9 or from 
death receptor signaling via caspase 8, independent of mitochondria, as well as through 
other pro-apoptotic pathways inside the cell (Cohen, 1997; Porter and Janicke, 1999).  
Caspase 3 cleaves a variety of crucial intracellular proteins including endonucleases, 
cytoskeletal components, and enzymes that lead to characteristic morphology of 
apoptosis. More upstream, Bax is a proapoptotic Bcl-2 protein. In healthy cells, the 
majority of Bax is found in the cytosol, but upon initiation of apoptotic signaling, bax 
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undergoes a conformation shift and inserts into the outer mitochondrial membrane.  Thus 
upregulation of Bax is associated with mitochondrial membrane permeabilization and 
release of pro apoptotic factors from mitochondria, leading to activation of caspases.  The 
reduction of caspase 3 activity and Bax expression by estradiol and phytoestrogens 
suggest that these compounds disrupt apoptotic signaling by downregulating key pro 
apoptotic factors in the cell death cascade.  As multiple apoptotic pathways converge on 
mitochondria functioning and caspase 3 activation, Bax and caspase 3 represent potential 
upstream and downstream check points for the attenuation of apoptosis by estrogenic 
compounds in response to neurodegenerative insults.  
We then sought to determine if these receptor-mediated effects were specific to a 
particular ER-subtype.  The ERα-specific antagonist MPP dihydrochloride and ERβ-
specific antagonist PHTPP did attenuate genistein and daidzein downregulation of 
caspase 3 activity. Similar to previous results observed with estradiol, both ER subtypes 
seem to play a role in genistein and daidzein actions on Tat activation of caspase 3.  A 
comparable profile was observed with genistein effects on Bax in the presence of ER 
subtype antagonists.  Both ER subtypes appear to mediate genistein effects on Bax 
expression as significant attenuation was achieved with both antagonists.  However, a 
more robust attenuation of genistein effects on Bax expression, even above levels 
achieved in cultures treated with Tat alone, was observed in the presence of PHTPP. 
These results indicate that genistein effects on Bax expression may be preferential for 
ERβ-mediated signaling.  Our results also demonstrate that significant attenuation of 
daidzein effects on Bax expression was achieved with the addition of both ER subtype 
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antagonists, suggesting involvement of both ERα and ERβ in daidzein downregulation of 
Bax.   It is possible that daidzein’s lower binding affinity for ERs compared to that of 
genistein and estradiol may explain the absence of the preferential mediation of a specific 
ER subtype.    
Importance of ERβ 
 The recent discovery of a second isoform of the estrogen receptor (ERβ) has 
generated intense interest in its potential role in estrogen signaling. In the adult rat, the 
cerebral cortex appears to predominantly express ERβ (Shughrue et al., 1997).  Studies 
using a rat model of stroke found estadiol to ameliorate the tissue loss associated with 
stroke in the cerebral cortex, initially implicating ERβ as the mediator of this protective 
effect (Dubal et al., 1998).  However, studies using transfected cells as well as knockout 
mice have suggested that ERα.  not ERβ, mediates protection against toxicity associated 
with middle cerebral arterial occlusion in addition to other toxic insults including β-
amyloid toxicity. Some studies have found that ERα does not appear to mediate the 
protective effects of 17β-estradiol, suggesting that there may be multiple mechanisms 
mediating estrogenic effects depending on the trigger and specific cellular 
responsiveness. The present study demonstrates a potential role for ERβ in protection. 
Although both ER subtypes were detected in our cultures, this was not a quantitative 
measure and it is likely that ERα expression may be very low in our primary cortical 
cultures as seen in prior studies assessing ER expression on cortical cultures (Linford and 
Dorsa, 2002).  Due to the high ERβ presence in the cerebral cortex, combined with the in 
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vitro selectivity of genistein and daidzein for ERβ, this subtype likely mediates the 
protective effects of phytoestrogens.  Recent evidence using an ERβ mouse knockout 
model shows that the absence of ERβ in development leads to an increase in cortical 
neuron loss, suggesting that ERβ may play an anti-apoptotic role in normal cerebral 
cortical development (Wang et al., 2001).     
Mitochondria have a vital role in neurodegeneration as well as neuroprotective 
mechanisms. The role of mitochondrial in apoptotic pathways is well established. In 
addition, recent studies report the ERβ is localized in the mitochondrial membrane. Our 
results suggest that the preferential involvement of  ERβ- mediated signaling in 17β-
estradiol and genistein effects on Bax may be related to localization of ERβ in 
mitochondria membrane. Estrogen and phytoestrogen attenuation of Tat-induced 
apoptotic signaling likely occurs via binding of estrogen receptors on the mitochondrial 
membrane and the direct regulation of proapoptotic proteins.  
It is widely accepted that estrogen actions are mediated by its receptors ERα and 
ERβ. These receptors can exist and act as homodimers as well as heterodimers, 
suggesting functional interaction between these two ERs (Toran-Allerand et al., 1999).  
Classical genomic mechanisms of estrogen action may not completely explain the 
complex and extensive range of estrogen action in the brain.  In addition to direct ER 
mediated effects, the  estrogenic response has been shown to interact with many second 
messengers, which may mediate receptor independent effects. Indirect nongenomic 
pathways have been shown to mediate estrogenic responses. Estrogenic neuroprotection 
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has been associated with PI-3 kinase activation, CREB phosphorylation, MAPK 
activation, and elevation in Bcl-2 mRNA.  Additionally it has been determined that 
estrogenic compounds can confer protection independent of estrogen receptor signaling 
(Linford and Dorsa, 2002). PI-3 kinase activation and MAPK activation have been 
directly linked to a reduction in intracellular caspase 3 activity, as well as being 
downstream of estrogen receptor signaling in neurons (Zhou et al, 2000; Zhang et al., 
2001).  For instance, the phosphorylation of the ER is now well established and it was 
shown to modulate ER ability to promote the transcription of estrogen-response-element 
controlled sequences as well as via the MAP-kinase pathway.  In addition, several studies 
provide evidence for the existence of signal cross-talk between the ER and other second 
messengers.  Although the question of whether phytoestrogens act via the same cellular 
pathways as estradiol or involve post-transcriptional events and/or membrane effects 
remains a topic of debate; however, our results have interesting implications in the 
understanding of the effect of phytoestrogens on brain function.  
Studies have indicated that estrogen and phytoestrogens exhibit different effects 
depending on the concentration.  In addition to the genomic and nongenomic 
mechanisms, these compounds are can act as potent anti-oxidants. Genistein is known to 
inhibit the activity of tyrosine kinases (Akiyama and Ogawara, 1991) and topoisomerase 
II (Markovits et al., 1989).  However, these effects are thought to occur at high µM 
concentrations. Neurotoxic effects of genistein and daidzein were also demonstrated with 
high doses in range of 50-100µM, which are significantly higher than the doses used in 
the present experiments.  Moreover, this antioxidant  and tyrosine kinase inhibition 
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activities usually require higher concentrations than needed for receptor-mediated 
activity. Our data suggest that there is specific ER modulation of the apoptotic cascade, 
thus attenuating neuronal cell death, rather than antioxidant or tyrosine kinase inhibition 
effects.   
Soy-derived extract preparations have been the most common form used in 
phytoestrogen intervention studies.  However, variations in relative composition could be 
significant among soy extracts obtained from different sources of soy plants and 
manufactured using different protocols, bringing into question the safety and efficacy of 
random mixtures.  The relative content of each isoflavone in soy-derived extract 
preparations may greatly influence the efficacy and safety phytoestrogen supplements. 
Although our studies demonstrate that individual isoflavones were capable of producing 
neuroprotective effects of the same magnitude as estradiol, Some studies suggest that 
select combination of phytoestrogens can elicit a stronger neuroprotective response and 
enhance ERβ-binding selectivity (Zhao et al., 2009).  With the wide use of phytoestrogen 
supplements as alternative to hormone therapy, understanding the efficacy of individual 
isoflavone versus when they are used in combination would be of great value as possible 
antagonistic interactions could occur in random mixtures from soy extracts. 
As estrogen receptors are thought to play a major role in mediating estrogen 
effects, delineating their role in the neuroprotective versus negative proliferative actions 
of estrogen remains a central focus of current research.  Studies have reported that soy 
isoflavones preferentially bind ERβ over ERα.  With the more abundant expression of 
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ERβ in the brain, it is suggested that this ER subtype is more involved in the 
neuroprotective actions of estradiol and phytoestrogens. The use of an ERβ selective 
agonist represents a viable therapeutic option to elicit the beneficial effects of estrogens 
without inducing the negative proliferative effects associated with estrogen therapy.   
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CHAPTER V 
General Discussion 
Estrogen deficient states may partly account for declines in cognition and 
neurodegeneration that are associated with dementia, such as HAD. The neuroprotective 
actions of estrogen have been demonstrated in many experimental models of 
neurodegenerative disease, including various dementias (Pike et al., 2009; Wilson et al., 
2006).  However, the mechanisms underlying the beneficial effect of estrogen are not 
well understood (Green & Simpkins, 2000). It is widely accepted that the biological 
actions of estrogen are mediated by two different receptor subtypes, ERα and ERβ.  
However, prolonged estrogen therapy is associated with increased risk of uterine and 
breast cancers. Thus, deciphering the roles of estrogen receptors in estrogenic processes 
is critical to developing therapeutic approaches that target the beneficial effects of 
estrogen and avoid unwanted side effects.  
The observations that the viral regulatory protein Tat is actively secreted by 
infected cells, and that Tat mRNA is elevated in the patients with HIV dementia suggest a 
possible role of extracellular Tat in the progression of HAD. Accordingly, Tat has been 
shown to have direct toxic effects on neurons that included increased production of ROS 
indicating oxidative stress, mitochondrial dysfunction, and apoptotic cell death.  
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The current series of experiments determined the neuroprotective efficacy of 
endogenous estrogen, 17β-estradiol and phytoestrogens, genistein and daidzein, against 
HIV-1 Tat induced cell death.  The results observed in the present series of experiments, 
demonstrate a common magnitude of neuroprotective effect of endogenous 17β-estradiol 
and phytoestrogens, mediated by similar estrogen receptor activation.  
Estrogen deficiency is associated with increased risk for dementia such as 
Alzheimer’s disease indicating that estrogens are a key factor in susceptibility to 
neurodegenerative disease and thus may be essential to neuroprotective processes. In 
Experiment 1, we demonstrate that estradiol was effective in attenuating HIV-1 Tat-
induced cell death.  Numerous studies have evaluated the neurotoxic potential of Tat, 
which includes the induction of apoptotic cell death.  However, the mechanism(s) 
underlying this cell death and the time course of Tat-mediated neurodegeneration is not 
well-understood.  In accordance with previously reported results, that Tat exposure 
induces mitochondrial dysfunction and production of ROS (Aksenov et al., 2001:2003), 
we show that apoptotic cell death, as determined by the activation of caspases, was 
initiated early after Tat exposure. This caspase activity was maintained over 24hrs and 
preceded the significant loss of cell viability in Tat exposed cultures. Moreover, we 
demonstrate a direct interaction of Tat with neurons expressing caspase activity.  In 
addition Tat-induced cell death involved the activation of the mitochondria-mediated 
apoptotic cascade. Key regulators of this cascade such as the proapoptotic protein Bax 
and active caspase 9 and caspase 3 were increased early after Tat exposure. Estrogen 
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attenuation of cell death involved down regulation of these mitochondria specific 
apoptotic markers.  Such observations support the findings that that estrogen is protective 
against oxidative stress-mediated apoptosis. 
Many of the physiological actions of estrogens are mediated by the two estrogen 
receptor subtypes, ERα and ERβ that belong to the nuclear receptor superfamily.  The 
differential expression and distribution of the ERs play a major role in the many 
physiological processes mediated by estrogens.  However, estrogen therapy is associated 
with negative side effects, mainly increased risk of ovarian and breast cancer. Delineating 
the mechanisms underlying the actions of estrogen will be essential in targeting its 
beneficial effects with minimal side effects.  This experiment illustrates the ability of 
17β-estradiol to attenuate some aspects of Tat-induced apoptotic cell death. Since 
estradiol pretreatment was able to downregulate the expression/activity of mitochondria 
specific apoptotic markers, this supports a strong role for genomic effects in estradiol-
mediated attenuation of the mitochondrial apoptotic cascade.  Our experiments evaluating 
the mechanism of estradiol neuroprotection against Tat-induced neurodegeneration reveal 
that ERs mediate select aspects of apoptotic cascade. Particularly, estrogen receptors 
mediate the pro-apoptotic protein Bax expression, which along with Bcl-2, monitors 
mitochondria membrane permeability, and capsase 3, an effector caspase.  This indicates 
that mitochondria membrane function and the execution phase of the apoptotic cascade 
represent key targets of apoptotic intervention.  We also demonstrate the differential 
involvement of ER subtypes in mediating estrogen effects. Both ER subtypes seem to 
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play a role in estrogen effects on caspase 3 while estrogen effects on Bax expression are 
mediated more so by ERβ. The ERβ specific effects on Bax, may be related to the recent 
discovery of ERβ localization in mitochondria, suggesting a direct estrogen effect on 
mitochondria function via ERβ activation and signaling.  
The functions of ERβ are of particular importance in understanding the 
neuroprotective strategies exhibited by estrogen. It has become clear that ERβ has 
functions that are distinct from those of ERα.  Studies in ER knockout mice indicate that 
ERα is the main player in mediating female reproductive functions whereas ERβ is more 
important in non-classical target tissues, such as central nervous systems (Harris, 2007). 
Targeting ERβ function may be a potential therapeutic option in neurodegenerative 
disease, since it is highly expressed in the brain, specifically in cortical regions 
responsible for executive cognitive functioning, which is significantly affected in HIV-1 
associated neurocognitive disorders (HAND).  
Further experiments sought to evaluate if potential ERβ selective agonists are 
equally effective as endogenous estradiol against Tat-induced apoptotic cell death. 
Phytoestrogens are plant-derived nonsteroidal compounds that are structurally similar to 
estrogens and thus induce estrogenic responses. Since the discovery that phytoestrogens 
can bind and activate ER, particularly interesting was the finding that many 
phytoestrogens bind with a higher affinity to ERβ compared to ERα, suggesting that they 
may induce physiological effects through this ER subtype. We observe that 
phytoestrogens genistein and daidzein exhibit a similar magnitude of protection as 
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estradiol against Tat-induced apoptotic cell death. Genistein and daidzein significantly 
attenuated the expression of apoptotic markers specific to the mitochondria apoptotic 
pathway.  Moreover these effects were also mediated by estrogen receptors. However, 
receptor mediated effects of genistein were more similar to estradiol than daidzein. These 
observations indicate that phytoestrogens attenuate Tat-induced cell death at a 
comparable magnitude and via estrogen receptor signaling. In addition, genistein closely 
modeled the receptor-mediated effects of estradiol, unlike daidzein.  
Although phytoestrogens are thought to preferentially bind ERβ, the degree to 
which a compound binds the ER may not necessarily reflect its ability of activate ER 
signaling. In a study using radioligand binding assay, genistein was shown to have a 
higher binding affinity than daidzein for ERβ and have a higher/stronger transcriptional 
potency. Of note is that the concentrations of phytoestrogen required to activate 
transcription through both ERα and ERβ are generally 1µM or less, which are 
concentrations physiologically achievable in humans after consumption of phytoestrogen 
rich foods or supplements. In tissues, expressing both ER subtypes activation of ERα and 
ERβ may occur.  
It should be considered that even though the individual purified phytoestrogens 
and their metabolites can bind and activate ERs, in regard to human exposure to 
phytoestrogens do not represent single compounds, but a mixture of different 
phytoestrogens and metabolites. The mixtures may induce different physiological effects 
compared to a single phytoestrogenic compound. A recent study found that a select 
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combination of phytoestrogens may enhance ERβ activation and binding.  It was shown 
that when genistein, daidzein, and equol were combined, the selectivity for ERβ binding 
increased, compared to genistein alone (Zhao et al.,2009). Moreover, the effects of these 
combinations in cells coexpressing ERα and ERβ may also display differential 
transcriptional activity when exposed to mixtures of different phytoestrogens.  
 In addition to neuronal loss, synaptodendritic pruning has also been implicated to 
underlie the cognitive dysfunction observed with HIV infection in the CNS. Studies have 
shown that Tat exposure caused loss of synapses before cell death was observed. 
Moreover, in contrast to cell death, synaptic degradation can be reversed. Future 
investigations should consider if estradiol and phytoestrogen protective effects against 
Tat induced neurodegeneration involves preservation of neuronal networks and synaptic 
density. Furthermore, to better model human consumption of soy products and easily 
available supplements, a combination of phytoestrogens should be used to determine their 
effects against neurogenerative insults.  
 With the success of HAART on viral suppression, viral production still persists in 
the brain, allowing the continued release and exposure to toxic viral proteins. The 
inability of anti-retroviral therapy to prevent the development of cognitive dysfunction 
indicates the need for alternative therapies that may ameliorate the neurodegenerative and 
subsequent neurologocial disturbances associated with NeuroAIDS. Findings in the 
present study demonstrate that phytoestrogens offer a similar magnititude of protective 
effect as endogenous estradiol via a selective estrogen receptor -mediated mechanism 
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against HIV-1 Tat-induced cell death.  Phytoestrogens, acting as selective ER agonists 
targeting the neuroprotective effects associated with estradiol, may be represent a viable 
adjuvant therapy with HAART combat NeuroAIDS. 
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